<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006817.pub2" GROUP_ID="NEONATAL" ID="745607043010295830" MERGED_FROM="" MODIFIED="2012-06-13 03:04:07 +0100" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;/p&gt;&lt;p&gt;CL 4/07 protocol&lt;/p&gt;" NOTES_MODIFIED="2012-06-12 22:02:34 -0400" NOTES_MODIFIED_BY="Diane Haughton" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2012-06-12 21:59:51 -0400" MODIFIED_BY="Diane Haughton">
<TITLE MODIFIED="2012-04-03 12:12:27 -0400" MODIFIED_BY="[Empty name]">Allopurinol for preventing mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathy</TITLE>
<CONTACT>
<PERSON ID="11151" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>William</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McGuire</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Child Health</POSITION>
<EMAIL_1>William.McGuire@hyms.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Hull York Medical School &amp; Centre for Reviews and Dissemination, University of York</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>York</CITY>
<ZIP/>
<REGION>Y010 5DD</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>44 01904 321695</PHONE_1>
<PHONE_2/>
<FAX_1>44 01904 321696</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-06-12 21:59:51 -0400" MODIFIED_BY="Diane Haughton">
<PERSON ID="252697EC82E26AA200CD32E5747E0C17" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tejasvi</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chaudhari</LAST_NAME>
<SUFFIX/>
<POSITION>Neonatal Fellow</POSITION>
<EMAIL_1>Tejasvi.Chaudhari@hnehealth.nsw.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>John Hunter Children's Hospital</ORGANISATION>
<ADDRESS_1>Lookout Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>New Lambton</CITY>
<ZIP>2305</ZIP>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11151" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>William</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McGuire</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Child Health</POSITION>
<EMAIL_1>William.McGuire@hyms.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Hull York Medical School &amp; Centre for Reviews and Dissemination, University of York</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>York</CITY>
<ZIP/>
<REGION>Y010 5DD</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>44 01904 321695</PHONE_1>
<PHONE_2/>
<FAX_1>44 01904 321696</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-05-07 17:17:29 -0400" MODIFIED_BY="Diane Haughton">
<UP_TO_DATE>
<DATE DAY="4" MONTH="4" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="4" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="25" MONTH="4" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2012-06-11 15:49:39 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-05-07 17:12:46 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>This updates the review 'Allopurinol for preventing mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathy' (<LINK REF="REF-Chaudhari-2008" TYPE="REFERENCE">Chaudhari 2008</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-06-11 15:49:39 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>Updated search March 2012.</P>
<P>No new trials identified but newly published additional neurodevelopmental outcome data from two trials included (Kaandorp 2012). No change to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-10-05 15:15:00 -0400" MODIFIED_BY="Diane Haughton">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-05 15:15:00 -0400" MODIFIED_BY="Diane Haughton">
<DATE DAY="13" MONTH="12" YEAR="2007"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-04-19 14:24:59 -0400" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-04-04 12:42:36 -0400" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-04-04 12:42:36 -0400" MODIFIED_BY="[Empty name]">
<NAME>HYMS &amp; NIHR Centre for Reviews and Dissemination, University of York</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-04-19 14:24:59 -0400" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-04-19 14:24:59 -0400" MODIFIED_BY="[Empty name]">
<NAME>Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201100016C</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-06-12 22:01:17 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-04-03 12:19:11 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-04-03 12:18:55 -0400" MODIFIED_BY="[Empty name]">Allopurinol for preventing mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathy</TITLE>
<SUMMARY_BODY MODIFIED="2012-04-03 12:19:11 -0400" MODIFIED_BY="[Empty name]">
<P>Newborn infants who have been deprived of oxygen before, during, or after delivery (perinatal asphyxia) are at high risk of dying or developing brain damage. Studies using animal models suggest that allopurinol (a drug commonly used for preventing gout) can reduce the level of brain damage following perinatal asphyxia. Three small randomised controlled trials that examined whether giving allopurinol to newborn infants following perinatal asphyxia affected their outcomes were identified. None of these trials provided any evidence of benefit. Larger trials are needed to exclude important effects on survival and disability.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-06-11 15:51:36 -0400" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-04-03 12:25:05 -0400" MODIFIED_BY="[Empty name]">
<P>Delayed neuronal death following a perinatal hypoxic insult is due partly to xanthine oxidase-mediated production of cytotoxic free radicals. Evidence exists that allopurinol, a xanthine-oxidase inhibitor, reduces delayed cell death in experimental models of perinatal asphyxia and in people with organ reperfusion injury.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-04-03 12:12:17 -0400" MODIFIED_BY="[Empty name]">
<P>To determine the effect of allopurinol on mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-04-04 12:35:25 -0400" MODIFIED_BY="[Empty name]">
<P>We used the standard search strategy of the Cochrane Neonatal Group. We searched the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I>, 2012, Issue 1), MEDLINE (1966 to March 2012), EMBASE (1980 to March 2012), CINAHL (1982 to March 2012), conference proceedings, and previous reviews.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-04-03 12:14:59 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised or quasi-randomised controlled trials that compared allopurinol administration versus placebo or no drug in newborn infants with hypoxic-ischaemic encephalopathy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-04-03 12:15:42 -0400" MODIFIED_BY="[Empty name]">
<P>We extracted data using the standard methods of the Cochrane Neonatal Review Group with separate evaluation of trial quality and data extraction by two review authors.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-06-11 15:51:36 -0400" MODIFIED_BY="[Empty name]">
<P>We included three trials in which a total of 114 infants participated. In one trial, participants were exclusively infants with severe encephalopathy. The other trials also included infants with mild and moderately severe encephalopathy. These studies were generally of good methodological quality, but were too small to exclude clinically important effects of allopurinol on mortality and morbidity. Meta-analysis did not reveal a statistically significant difference in the risk of death (typical risk ratio 0.88; 95% confidence interval (95% CI) 0.56 to 1.38; risk difference -0.04; 95% CI -0.18 to 0.10) or a composite of death or severe neurodevelopmental disability (typical risk ratio 0.78; 95% CI 0.56 to 1.08; risk difference -0.14; 95% CI -0.31 to 0.04).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-04-07 05:26:13 -0400" MODIFIED_BY="[Empty name]">
<P>The available data are not sufficient to determine whether allopurinol has clinically important benefits for newborn infants with hypoxic-ischaemic encephalopathy. Much larger trials are needed. Such trials could assess allopurinol as an adjunct to therapeutic hypothermia in infants with moderate and severe encephalopathy and should be designed to exclude important effects on mortality and adverse long-term neurodevelopmental outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-06-12 22:01:17 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-06-11 15:50:42 -0400" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-06-11 15:50:42 -0400" MODIFIED_BY="[Empty name]">
<P>Hypoxic-ischaemic encephalopathy is a major cause of death and of disability in newborn infants worldwide (<LINK REF="REF-Kurinczuk-2010" TYPE="REFERENCE">Kurinczuk 2010</LINK>). The severity of the encephalopathy predicts the risk of death and long-term neurodevelopmental impairment (<LINK REF="REF-Sarnat-1976" TYPE="REFERENCE">Sarnat 1976</LINK>; <LINK REF="REF-Vannucci-1997" TYPE="REFERENCE">Vannucci 1997</LINK>; <LINK REF="REF-Gonzalez-2006" TYPE="REFERENCE">Gonzalez 2006</LINK>). Brain damage following a perinatal hypoxic-ischaemic insult occurs in two phases. Early cell death results from primary exhaustion of the cellular energy stores. A second phase of cell death occurs during reperfusion and reoxygenation several hours after the initial insult. The pathophysiology of late neuronal damage involves the production of cytotoxic free radicals (including hydrogen peroxide, superoxides, free iron and hydroxyl radicals) that damage cell lipids, proteins, and nucleic acids, and results in secondary energy failure, membrane dysfunction, and apoptosis (<LINK REF="REF-Inder-2000" TYPE="REFERENCE">Inder 2000</LINK>). The degree of secondary energy failure is predictive of mortality and neurodevelopmental impairment (<LINK REF="REF-Roth-1997" TYPE="REFERENCE">Roth 1997</LINK>). Various pharmacological and non-pharmacological interventions that may limit free-radical generation and minimise the extent of late cell death are the subject of other Cochrane reviews (<LINK REF="REF-Hunt-2002" TYPE="REFERENCE">Hunt 2002</LINK>; <LINK REF="REF-McGuire-2004" TYPE="REFERENCE">McGuire 2004</LINK>; <LINK REF="REF-Kecskes-2005" TYPE="REFERENCE">Kecskes 2005</LINK>; <LINK REF="REF-Beveridge-2006" TYPE="REFERENCE">Beveridge 2006</LINK>; <LINK REF="REF-Evans-2007" TYPE="REFERENCE">Evans 2007</LINK>; <LINK REF="REF-Jacobs-2007" TYPE="REFERENCE">Jacobs 2007</LINK>). With the exception of therapeutic mild hypothermia, none of these interventions has yet been proven to limit brain damage in newborn infants with hypoxic-ischaemic encephalopathy (<LINK REF="REF-Edwards-2006" TYPE="REFERENCE">Edwards 2006</LINK>; <LINK REF="REF-Jacobs-2007" TYPE="REFERENCE">Jacobs 2007</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]">
<P>In part, the production of cytotoxic free radicals is dependent on xanthine oxidase-mediated metabolism of hypoxanthine (<LINK REF="REF-Warner-2004" TYPE="REFERENCE">Warner 2004</LINK>). Studies using experimental animal models have found that the xanthine oxidase inhibitor allopurinol and its metabolic product, oxypurinol, reduce free-radical formation and limit the degree of post-asphyxia brain damage (<LINK REF="REF-Palmer-1990" TYPE="REFERENCE">Palmer 1990</LINK>; <LINK REF="REF-Palmer-1991" TYPE="REFERENCE">Palmer 1991</LINK>; <LINK REF="REF-Palmer-1993" TYPE="REFERENCE">Palmer 1993</LINK>; <LINK REF="REF-Van-Bel-1998" TYPE="REFERENCE">Van Bel 1998</LINK>). At high concentrations, allopurinol scavenges free radicals such as hydroxyl, chelates free iron, and inhibits lipid peroxidation and heat shock factor expression (<LINK REF="REF-Pacher-2006" TYPE="REFERENCE">Pacher 2006</LINK>). Evidence from randomised controlled trials suggests that high-dose allopurinol (&gt; 10 mg/kg) reduces reperfusion injury in adults who undergo coronary bypass surgery (<LINK REF="REF-Johnson-1991" TYPE="REFERENCE">Johnson 1991</LINK>; <LINK REF="REF-Sisto-1995" TYPE="REFERENCE">Sisto 1995</LINK>). In newborn infants with severe respiratory failure needing treatment with extracorporeal membrane oxygenation, high-dose allopurinol reduces free-radical production and injury (<LINK REF="REF-Marro-1997" TYPE="REFERENCE">Marro 1997</LINK>). In infants with hypoplastic left heart syndrome who undergo cardiac surgery using deep hypothermic circulatory arrest, pretreatment with allopurinol reduces postoperative adverse cardiac and neurological outcomes (<LINK REF="REF-Clancy-2001" TYPE="REFERENCE">Clancy 2001</LINK>).</P>
<P>The most commonly reported adverse effects of allopurinol are skin rashes and hypersensitivity reactions (<LINK REF="REF-Vazquez_x002d_Mellado-2001" TYPE="REFERENCE">Vazquez-Mellado 2001</LINK>). A very rare but severe hypersensitivity syndrome consisting of skin reactions (erythema multiforme, toxic epidermal necrolysis), fever, eosinophilia, and multiorgan failure has been described in people with concomitant renal impairment or thiazide diuretic use (<LINK REF="REF-Arellano-1993" TYPE="REFERENCE">Arellano 1993</LINK>; <LINK REF="REF-Kumar-1996" TYPE="REFERENCE">Kumar 1996</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2012-04-04 12:40:24 -0400" MODIFIED_BY="[Empty name]">
<P>Given the evidence of beneficial effects in experimental models and in people with other forms of organ reperfusion injury, and the potential for allopurinol to affect pathogenic pathways associated with delayed neuronal death, we reviewed the available evidence from randomised controlled trials of allopurinol for newborn infants with hypoxic-ischaemic encephalopathy to determine if there are any implications for current practice or for future research.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-04-03 12:26:05 -0400" MODIFIED_BY="[Empty name]">
<P>To determine the effect of allopurinol on mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-06-11 15:52:38 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Controlled trials using either random or quasi-random patient allocation.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]">
<P>Newborn infants (&gt; 34 weeks' gestation) with hypoxic-ischaemic encephalopathy defined as clinical evidence of cardiorespiratory or neurological depression (Apgar score &lt; 7 at five minutes and beyond after birth) and/or evidence of severe metabolic acidosis in intrapartum foetal, umbilical arterial cord, or very early neonatal blood samples (pH &lt; 7 or base deficit &gt; 12 mmol/L), and/or clinical or electro-encephalographic (multichannel or amplitude integrated) evidence of neonatal encephalopathy (<LINK REF="REF-MacLennan-1999" TYPE="REFERENCE">MacLennan 1999</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-04-03 12:27:12 -0400" MODIFIED_BY="[Empty name]">
<P>Allopurinol versus placebo or no drug administered within six hours of delivery. A minimum or maximum dose or duration of treatment was not pre-specified. Allopurinol could have been given in conjunction with another intervention provided both treatment and control groups received the intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-05-15 13:05:17 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<OL>
<LI>Death during infancy.</LI>
<LI>Death or severe neurodevelopmental disability in survivors assessed aged &#8805; 12 months of age, defined as any one or combination of the following: non-ambulant cerebral palsy, severe developmental delay assessed using validated tools, auditory and visual impairment (each component analysed individually as well as part of the composite outcome).</LI>
<LI>Cognitive and educational outcomes in survivors aged &gt; 5 years old (intelligence quotient and/or indices of educational achievement measured using a validated assessment tool including school examination results).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<OL>
<LI>Seizures in the neonatal period, either apparent clinically or detected by electro-encephalographic recordings.</LI>
<LI>Time to achieve full oral feeding independent of enteral tube feeding (days after birth), and/or incidence of continued enteral tube feeding at four weeks after birth.</LI>
<LI>Cortical, white matter, or basal ganglia abnormalities on brain imaging (magnetic resonance, computed tomography, or ultrasound).</LI>
<LI>Potential adverse effects of allopurinol (skin rashes, hypersensitivity reactions) that necessitates discontinuation of therapy.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]">
<P>We used the standard search strategy of the Cochrane Neonatal Review Group</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-05-15 13:05:32 -0400" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I>, Issue 1, 2012), MEDLINE (1966 to March 2012), EMBASE (1980 to March 2012), and CINAHL (1982 to March 2012) using a combination of the following text words and MeSH terms: [Infant, Newborn OR Asphyxia Neonatorum/ OR Hypoxia, Brain/ OR Brain Ischemia/ OR infant OR neonat*] AND [Allopurinol/ OR Free Radical Scavengers/ OR Free Radicals/ OR Antioxidants/]. The search outputs were limited with the relevant search filters for clinical trials as recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We did not apply any language restriction.</P>
<P>We searched <A HREF="http://clinicaltrials.gov/">ClinicalTrials.gov</A> and <A HREF="http://www.controlled-trials.com/">Current Controlled Trials</A> for completed or ongoing trials.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]">
<P>We examined the references in studies identified as potentially relevant. We also searched the abstracts from the annual meetings of the Pediatric Academic Societies (1993 to 2011), the European Society for Paediatric Research (1995 to 2011), the UK Royal College of Paediatrics and Child Health (2000 to 2012), and the Perinatal Society of Australia and New Zealand (2000 to 2012). We considered trials reported only as abstracts to be eligible if sufficient information was available from the report, or from contact with the authors, to fulfil the inclusion criteria.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-06-11 15:52:38 -0400" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of the Cochrane Neonatal Review Group.</P>
<STUDY_SELECTION MODIFIED="2012-04-03 12:49:12 -0400" MODIFIED_BY="[Empty name]">
<P>Two review authors screened the title and abstract of all studies identified by the above search strategy. We reassessed the full text of any potentially eligible reports and excluded those studies that did not meet all of the inclusion criteria. We discussed any disagreements until consensus was achieved.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-04-03 12:48:51 -0400" MODIFIED_BY="[Empty name]">
<P>We used a data collection form to aid extraction of relevant information from each included study. Two review authors extracted the data separately. We discussed any disagreements until consensus was achieved. We asked the investigators for further information if data from the trial reports were insufficient.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-05-15 13:05:55 -0400" MODIFIED_BY="[Empty name]">
<P>We used the criteria and standard methods of the Cochrane Neonatal Review Group to assess the methodological quality of any included trials. Additional information from the trial authors was requested to clarify methodology and results as necessary. We evaluated and reported the following issues in the 'Risk of bias' tables:</P>
<OL>
<LI>Sequence generation: we categorised the method used to generate the allocation sequence as:</LI>
<OL>
<LI>low risk: any random process (e.g. random number table; computer random number generator);</LI>
<LI>high risk: any non-random process (e.g. odd or even date of birth; patient case-record number);</LI>
<LI>unclear.</LI>
</OL>
<LI>Allocation concealment: we categorised the method used to conceal the allocation sequence as:</LI>
<OL>
<LI>low risk: (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk: open random allocation; unsealed or non-opaque envelopes, alternation; date of birth;</LI>
<LI>unclear.</LI>
</OL>
<LI>Blinding: we assessed blinding of participants, clinicians, carers, and outcome assessors separately for different outcomes and categorised the methods as</LI>
<OL>
<LI>low risk;</LI>
<LI>high risk;</LI>
<LI>unclear.</LI>
</OL>
<LI>Incomplete outcome data: we described the completeness of data including attrition and exclusions from the analysis for each outcome and any reasons for attrition or exclusion where reported. We assessed whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported or supplied by the trial authors, we re-included missing data in the analyses. We categorised completeness as:</LI>
<OL>
<LI>low risk: &lt; 20% missing data;</LI>
<LI>high risk: &#8805; 20% missing data;</LI>
<LI>unclear.</LI>
</OL>
</OL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-05-15 13:05:59 -0400" MODIFIED_BY="[Empty name]">
<P>We calculated risk ratio (RR) and risk difference (RD) for dichotomous data and weighted mean difference (WMD) for continuous data, with respective 95% confidence intervals (CI). We determined the number needed to treat for benefit (NNTB) or harm (NNTH) for analyses with a statistically significant difference in the RD.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-04-03 12:50:40 -0400" MODIFIED_BY="[Empty name]">
<P>The unit of analysis is the participating infant in individually randomised trials and the neonatal unit for cluster randomised trials.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-04-03 12:51:02 -0400" MODIFIED_BY="[Empty name]">
<P>We contacted the trial primary investigators to seek missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-05-15 13:06:07 -0400" MODIFIED_BY="[Empty name]">
<P>We examined the treatment effects of individual trials and heterogeneity between trial results by inspecting the forest plots. We calculated the I<SUP>2</SUP> statistic for each RR analysis to quantify inconsistency across studies and describe the percentage of variability in effect estimates that may be due to heterogeneity rather than sampling error. If substantial heterogeneity (I<SUP>2</SUP> &gt; 50%) was detected, we explored the possible causes (e.g. differences in study design, participants, interventions, or completeness of outcome assessments).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-04-03 12:52:03 -0400" MODIFIED_BY="[Empty name]">
<P>If data from more than five trials were included in a meta-analysis, we examined a funnel plot for asymmetry.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]">
<P>We used the fixed-effect model in RevMan 5.1 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) for meta-analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-06-11 15:52:38 -0400" MODIFIED_BY="[Empty name]">
<P>We specified these subgroup analyses:</P>
<OL>
<LI>Trials that assessed allopurinol as a sole therapy.</LI>
<LI>Trials of allopurinol as an adjunct to another therapy.</LI>
<LI>Severity of encephalopathy based on clinical features (<LINK REF="REF-Sarnat-1976" TYPE="REFERENCE">Sarnat 1976</LINK>):</LI>
</OL>
<UL>
<LI>mild: hyperalertness, hyperreflexia, dilated pupils, tachycardia, absence of seizures</LI>
<LI>moderate: lethargy, hyperreflexia, miosis, bradycardia, seizures, hypotonia with weak suck and Moro reflex</LI>
<LI>severe: stupor, flaccidity, small mid-position pupils that react poorly to light, decreased stretch reflexes, hypothermia, and absent Moro reflex</LI>
</UL>
<P>or nature of electroencephalogram (EEG) abnormality:</P>
<UL>
<LI>mild: electrographic seizures, dysmaturity</LI>
<LI>moderate: low voltage or discontinuous background</LI>
<LI>severe: isoelectric or burst-suppression pattern</LI>
</UL>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-06-12 22:01:17 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-06-11 15:13:47 -0400" MODIFIED_BY="[Empty name]">
<P>Three trials, in which a total of 114 infants participated, fulfilled eligibility criteria (<LINK REF="STD-van-Bel-1998" TYPE="STUDY">van Bel 1998</LINK>; <LINK REF="STD-Benders-2006" TYPE="STUDY">Benders 2006</LINK>; <LINK REF="STD-Gunes-2007" TYPE="STUDY">Gunes 2007</LINK>). These studies were conducted between 1995 and 2005 in neonatal intensive care centres in The Netherlands and Turkey. This update includes additional neurodevelopmental outcome data from <LINK REF="STD-van-Bel-1998" TYPE="STUDY">van Bel 1998</LINK> and <LINK REF="STD-Benders-2006" TYPE="STUDY">Benders 2006</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>The participants were term or late preterm infants with suspected perinatal asphyxia and hypoxic-ischaemic encephalopathy. In one trial, only infants with severe encephalopathy, defined on the basis of abnormal findings on amplitude-integrated EEG (aEEG), were eligible to participate (<LINK REF="STD-Benders-2006" TYPE="STUDY">Benders 2006</LINK>). In the other trials, infants with mild and moderately severe encephalopathy were also enrolled. Infants with major congenital anomalies or infections were excluded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>In all of the studies, infants received the intervention or control within four hours after birth. Allopurinol was given intravenously in total daily doses of 40 mg/kg of birth weight. <LINK REF="STD-Benders-2006" TYPE="STUDY">Benders 2006</LINK> and <LINK REF="STD-van-Bel-1998" TYPE="STUDY">van Bel 1998</LINK> continued treatment for one day. <LINK REF="STD-Gunes-2007" TYPE="STUDY">Gunes 2007</LINK> continued treatment for three days after birth.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>The trials reported short-term outcomes including mortality, seizure frequency, neuro-imaging findings, and biochemical measures of hepatic and renal function and assessed neurodevelopmental outcomes in surviving infants aged 18 months (<LINK REF="STD-Gunes-2007" TYPE="STUDY">Gunes 2007</LINK>) and at four to eight years (<LINK REF="STD-van-Bel-1998" TYPE="STUDY">van Bel 1998</LINK>; <LINK REF="STD-Benders-2006" TYPE="STUDY">Benders 2006</LINK>).</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-06-11 14:48:58 -0400" MODIFIED_BY="[Empty name]">
<P>Although small, the trials were generally of good methodological quality with adequate allocation concealment (randomisation in central pharmacy, computer-generated sequence in sealed opaque envelopes). One trial did not blind caregivers or assessors (<LINK REF="STD-van-Bel-1998" TYPE="STUDY">van Bel 1998</LINK>). All trials achieved complete or near-complete follow-up. Two trials reported intention-to-treat analyses. In <LINK REF="STD-Benders-2006" TYPE="STUDY">Benders 2006</LINK>, one infant who was diagnosed with a (probably genetic) condition associated with neurodevelopmental delay was excluded from analyses in the trial report. We have re-included outcomes for this infant in intention-to-treat analyses in this review.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-06-12 22:01:17 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Allopurinol versus control (Comparison 1)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes: death and neurodevelopmental disability</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Death during the neonatal period and during infancy (Outcome 1.1)</HEADING>
<P>Meta-analysis did not detect a statistically significant effect on death during the neonatal period or infancy: typical RR 0.88 (95% CI 0.56 to 1.38); typical RD -0.04 (95% CI -0.18 to 0.10) (3 studies; 114 infants); <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Death or severe neurodevelopmental disability in survivors (Outcome 1.2 and Outcome 1.3)</HEADING>
<P>Meta-analysis did not detect a statistically significant effect on death or severe neurodevelopmental disability in survivors: typical RR 0.78 (95% CI 0.56 to 1.08); typical RD -0.14 (95% CI -0.31 to 0.04) (3 studies; 110 infants); <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<P>There was no statistically significant difference in the rate of severe quadriplegia in surviving infants: typical RR 0.59 (95% CI 0.28 to 1.27); typical RD -0.14 (95% CI -0.35 to 0.06) (3 studies; 73 infants); <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<P>Data were not available for neurosensory impairments or developmental indices.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cognitive and educational outcomes</HEADING>
<P>Not assessed in any of the trials.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes: neonatal morbidity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Seizures in the neonatal period (Outcome 1.4)</HEADING>
<P>Meta-analysis did not detect a statistically significant effect on seizures in the neonatal period: typical RR 0.93 (95% CI 0.75 to 1.16); typical RD -0.05 (95% CI -0.21 to 0.11)(3 studies; 114 infants); <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Time to achieve full oral feeding</HEADING>
<P>Not reported by any of the trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Abnormalities on brain imaging (Outcome 1.5)</HEADING>
<P>Only <LINK REF="STD-Benders-2006" TYPE="STUDY">Benders 2006</LINK> reported this outcome. There was no statistically significant difference in the incidence of brain abnormalities assessed in the early neonatal period with ultrasound (RR 1.12; 95% CI 0.81 to 1.55; RD 0.10; 95% CI -0.17 to 0.36) or with magnetic resonance imaging in surviving infants (RR 1.88; 95% CI 0.56 to 6.31; RD 0.35; 95% CI -0.25 to 0.95); <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Potential adverse effects of allopurinol</HEADING>
<P>Not assessed in any of the trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analyses</HEADING>
<P>1. Allopurinol as a sole therapy: all of the included trials assessed allopurinol as a sole therapy.<BR/>2. Allopurinol as an adjunct to another therapy: none of the included trials assessed allopurinol in combination with another therapy.<BR/>3. Severity of encephalopathy: meta-analyses of outcome data from <LINK REF="STD-van-Bel-1998" TYPE="STUDY">van Bel 1998</LINK> and <LINK REF="STD-Benders-2006" TYPE="STUDY">Benders 2006</LINK> restricted to infants with severe encephalopathy defined by the detection of a burst suppression pattern or worse on aEEG at trial entry did not find statistically significant differences in mortality (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) or death or severe neurodevelopmental disability (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>
<LINK REF="STD-Gunes-2007" TYPE="STUDY">Gunes 2007</LINK> enrolled 19 infants with mild encephalopathy, 21 infants with moderately severe encephalopathy, and 20 infants with severe encephalopathy. Subgroup outcome data are not available.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-06-11 14:47:52 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-04-04 05:43:27 -0400" MODIFIED_BY="[Empty name]">
<P>There are limited data available from three small randomised controlled trials that assessed the effect of allopurinol in newborn infants with hypoxic-ischaemic encephalopathy. These trials did not find any evidence of an effect on mortality, severe disability, neonatal seizure frequency, or the incidence of abnormalities on brain imaging during the neonatal period. </P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-05-15 13:08:12 -0400" MODIFIED_BY="[Empty name]">
<P>Given the small number of infants who have participated in trials to date (n = 114), clinically important beneficial or harmful effects of allopurinol have not yet been excluded. Much larger trials similar to the efforts undertaken to assess the effect of therapeutic hypothermia for infants with hypoxic-ischaemic encephalopathy would be needed to exclude modest but clinically important effect sizes (<LINK REF="REF-Jacobs-2007" TYPE="REFERENCE">Jacobs 2007</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-06-11 14:47:52 -0400" MODIFIED_BY="[Empty name]">
<P>Although small, the trials were generally of good methodological quality with adequate allocation concealment (randomisation in central pharmacy, computer-generated sequence in sealed opaque envelopes). One trial did not blind caregivers or assessors (<LINK REF="STD-van-Bel-1998" TYPE="STUDY">van Bel 1998</LINK>). All trials achieved complete or near-complete follow-up neurodevelopmental assessment of survivors (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-05-15 14:58:46 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-04-04 10:39:22 -0400" MODIFIED_BY="[Empty name]">
<P>The available data are insufficient to determine whether allopurinol is beneficial as an adjunctive treatment for newborn infants with hypoxic-ischaemic encephalopathy. Modest but important effect sizes have not been excluded.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-05-15 14:58:46 -0400" MODIFIED_BY="[Empty name]">
<P>Further large trials to determine the effect of allopurinol on mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathy may be justified. Allopurinol is a simple and relatively inexpensive intervention. The biological plausibility for preventing hypoxic-ischaemic injury has been well-established in pre-clinical studies and experiments using animal models (<LINK REF="REF-Warner-2004" TYPE="REFERENCE">Warner 2004</LINK>; <LINK REF="REF-Robertson-2012" TYPE="REFERENCE">Robertson 2012</LINK>). The available data have not raised major safety concerns related to use in newborn infants. Trials in which other patient groups have participated have found some evidence of benefit in limiting tissue reperfusion injuries (<LINK REF="REF-Johnson-1991" TYPE="REFERENCE">Johnson 1991</LINK>; <LINK REF="REF-Sisto-1995" TYPE="REFERENCE">Sisto 1995</LINK>; <LINK REF="REF-Marro-1997" TYPE="REFERENCE">Marro 1997</LINK>; <LINK REF="REF-Clancy-2001" TYPE="REFERENCE">Clancy 2001</LINK>).</P>
<P>Since evidence exists that mild systemic or head hypothermia reduces mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathy (<LINK REF="REF-Jacobs-2007" TYPE="REFERENCE">Jacobs 2007</LINK>), allopurinol or any other therapies that aim to minimise delayed neuronal damage following perinatal asphyxia should be assessed as an adjunct to hypothermia in future trials (<LINK REF="REF-Perlman-2006" TYPE="REFERENCE">Perlman 2006</LINK>). Hypothermia is thought to prevent neuronal death by reducing cellular metabolic rates and inhibiting multiple cytotoxic pathways including the generation of free radicals and the accumulation of hypoxanthine (<LINK REF="REF-Vannucci-1997" TYPE="REFERENCE">Vannucci 1997</LINK>). It is not known whether adjunctive specific inhibition of these pathways with allopurinol is of any additional or synergistic value (<LINK REF="REF-Robertson-2012" TYPE="REFERENCE">Robertson 2012</LINK>). Furthermore, the effect of hypothermia on the pharmacokinetics of allopurinol and oxypurinol has not been explored (<LINK REF="REF-McGaurn-1994" TYPE="REFERENCE">McGaurn 1994</LINK>; <LINK REF="REF-van-Kesteren-2006" TYPE="REFERENCE">van Kesteren 2006</LINK>). Several other issues relating to trials of interventions for newborn infants with hypoxic-ischaemic encephalopathy have been highlighted (<LINK REF="REF-Perlman-2006" TYPE="REFERENCE">Perlman 2006</LINK>):</P>
<OL>
<LI>Inclusion criteria should be simple and pragmatic to allow the trial conclusions to be widely applicable, particularly to rural and remote settings and middle- and low-income countries where the burden of hypoxic-ischaemic encephalopathy is greatest (<LINK REF="REF-Kurinczuk-2010" TYPE="REFERENCE">Kurinczuk 2010</LINK>).</LI>
<LI>Infants with either moderate or severe neonatal encephalopathy should be eligible to participate since evidence exists that therapeutic hypothermia benefits infants in both of these prognostic categories (<LINK REF="REF-Jacobs-2007" TYPE="REFERENCE">Jacobs 2007</LINK>).</LI>
<LI>Trials should assess more than short-term and surrogate outcomes. Since interventions that reduce mortality in infants with hypoxic-ischaemic encephalopathy may result in higher rates of adverse neurological outcomes, long-term follow-up should be planned to assess the effect on neurodevelopmental and cognitive outcomes (<LINK REF="REF-Gonzalez-2006" TYPE="REFERENCE">Gonzalez 2006</LINK>). A priori agreements between research groups on the use of standard neurodevelopmental assessments (as well as trial entry criteria and intervention dose and duration) would ease incorporation of data from future trials into meta-analyses to improve precision of effect size estimates.</LI>
<LI>The 'therapeutic window' for minimising post-asphyxial secondary neuronal death is less than about six hours after birth (<LINK REF="REF-Inder-2000" TYPE="REFERENCE">Inder 2000</LINK>). Approaching parents about their infant's participation in a clinical trial is very difficult during this time. Informing parents antenatally about the possible need for emergency intervention around the time of birth may help to increase recruitment rates without compromising parental understanding of the nature and purpose of the research. Research efforts have also examined the possibility of antenatal administration of allopurinol to women in labour where there is concern about perinatal asphyxia (<LINK REF="STD-Torrance-2009" TYPE="STUDY">Torrance 2009;</LINK> <LINK REF="STD-Kaandorp-2010" TYPE="STUDY">Kaandorp 2010</LINK>). It may be that transplacental allopurinol for compromised fetuses (perhaps with further doses given postnatally to infants with encephalopathy) is considered as a model for future evaluation.</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]">
<P>We thank Dr. Joepe Kaandorp for providing unpublished data from <LINK REF="STD-van-Bel-1998" TYPE="STUDY">van Bel 1998</LINK> and <LINK REF="STD-Benders-2006" TYPE="STUDY">Benders 2006</LINK>.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-04-03 12:55:02 -0400" MODIFIED_BY="[Empty name]">
<P>Tejesvi Chaudhari and William McGuire developed the protocol, performed the electronic and hand searches, screened the title and abstract of all studies identified, and the full text of potentially relevant reports. Each author independently assessed the methodological quality of the included trials, extracted the relevant information and data, and completed the final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-04-07 05:37:27 -0400" MODIFIED_BY="[Empty name]">
<P>None.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-04-19 14:35:55 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-04-19 14:30:53 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Benders-2006" MODIFIED="2012-04-19 14:30:53 -0400" MODIFIED_BY="[Empty name]" NAME="Benders 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-04-04 12:45:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Benders MJ, Bos AF, Rademaker CM, Rijken M, Torrance HL, Groenendaal F, et al</AU>
<TI>Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia</TI>
<SO>Archives of Disease in Childhood Fetal &amp; Neonatal Edition</SO>
<YR>2006</YR>
<VL>91</VL>
<PG>F163-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-19 14:30:53 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaandorp JJ, van Bel F, Veen S, Derks JB, Groenendaal F, Rijken M, et al</AU>
<TI>Long-term neuroprotective effects of allopurinol after moderate perinatal asphyxia: follow-up of two randomised controlled trials</TI>
<SO>Archives of Disease in Childhood Fetal &amp; Neonatal Edition</SO>
<YR>2012</YR>
<VL>97</VL>
<PG>F162-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gunes-2007" NAME="Gunes 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gunes T, Ozturk MA, Koklu E, Kose K, Gunes I</AU>
<TI>Effect of allopurinol supplementation on nitric oxide levels in asphyxiated newborns</TI>
<SO>Pediatric Neurology</SO>
<YR>2007</YR>
<VL>36</VL>
<PG>17-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Bel-1998" MODIFIED="2012-04-19 14:30:45 -0400" MODIFIED_BY="[Empty name]" NAME="van Bel 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-04-19 14:30:45 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaandorp JJ, van Bel F, Veen S, Derks JB, Groenendaal F, Rijken M, et al</AU>
<TI>Long-term neuroprotective effects of allopurinol after moderate perinatal asphyxia: follow-up of two randomised controlled trials</TI>
<SO>Archives of Disease in Childhood Fetal &amp; Neonatal Edition</SO>
<YR>2012</YR>
<VL>97</VL>
<PG>F162-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-19 14:28:25 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Bel F, Shadid M, Moison RM, Dorrepaal CA, Fontijn J, Monteiro L, et al</AU>
<TI>Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>185-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-04-19 14:35:55 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Kaandorp-2010" MODIFIED="2012-04-19 14:35:55 -0400" MODIFIED_BY="[Empty name]" NAME="Kaandorp 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-04-19 14:35:55 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaandorp JJ, Benders MJ, Rademaker CM, Torrance HL, Oudijk MA, de Haan TR, et al</AU>
<TI>Antenatal allopurinol for reduction of birth asphyxia induced brain damage (ALLO-Trial); a randomized double blind placebo controlled multicenter study</TI>
<SO>BMC Pregnancy and Childbirth</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>8</PG>
<IDENTIFIERS MODIFIED="2012-04-07 05:47:07 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20167117"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torrance-2009" MODIFIED="2012-04-07 05:47:43 -0400" MODIFIED_BY="[Empty name]" NAME="Torrance 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-04-07 05:47:43 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torrance HL, Benders MJ, Derks JB, Rademaker CM, Bos AF, Van Den Berg P, et al</AU>
<TI>Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>124</VL>
<PG>350-7</PG>
<IDENTIFIERS MODIFIED="2012-04-07 05:47:07 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19564319"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Arellano-1993" NAME="Arellano 1993" TYPE="JOURNAL_ARTICLE">
<AU>Arellano F, Sacristán JA</AU>
<TI>Allopurinol hypersensitivity syndrome: a review</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1993</YR>
<VL>27</VL>
<PG>337-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beveridge-2006" MODIFIED="2012-04-19 14:44:00 -0400" MODIFIED_BY="[Empty name]" NAME="Beveridge 2006" TYPE="COCHRANE_REVIEW">
<AU>Beveridge CJ, Wilkinson AR</AU>
<TI>Sodium bicarbonate infusion during resuscitation of infants at birth</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2012-04-19 14:44:00 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-19 14:44:00 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004864.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clancy-2001" MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]" NAME="Clancy 2001" TYPE="JOURNAL_ARTICLE">
<AU>Clancy RR, McGaurn SA, Goin JE, Hirtz DG, Norwood WI, Gaynor JW, et al</AU>
<TI>Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>108</VL>
<PG>61-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edwards-2006" NAME="Edwards 2006" TYPE="JOURNAL_ARTICLE">
<AU>Edwards AD, Azzopardi DV</AU>
<TI>Therapeutic hypothermia following perinatal asphyxia</TI>
<SO>Archives of Disease in Childhood Fetal &amp; Neonatal Edition</SO>
<YR>2006</YR>
<VL>91</VL>
<PG>F127-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-2007" MODIFIED="2012-04-19 14:38:08 -0400" MODIFIED_BY="[Empty name]" NAME="Evans 2007" TYPE="COCHRANE_REVIEW">
<AU>Evans DJ, Levene MI, Tsakmakis M</AU>
<TI>Anticonvulsants for preventing mortality and morbidity in full term newborns with perinatal asphyxia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-04-19 14:38:08 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-19 14:38:08 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001240.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gonzalez-2006" NAME="Gonzalez 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez FF, Miller SP</AU>
<TI>Does perinatal asphyxia impair cognitive function without cerebral palsy?</TI>
<SO>Archives of Disease in Childhood Fetal &amp; Neonatal Edition</SO>
<YR>2006</YR>
<VL>91</VL>
<PG>F454-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-15 13:10:30 -0400" MODIFIED_BY="Anne Lawson" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunt-2002" MODIFIED="2012-04-19 14:41:56 -0400" MODIFIED_BY="[Empty name]" NAME="Hunt 2002" TYPE="COCHRANE_REVIEW">
<AU>Hunt R, Osborn D</AU>
<TI>Dopamine for prevention of morbidity and mortality in term newborn infants with suspected perinatal asphyxia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2012-04-19 14:41:56 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-19 14:41:56 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003484"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Inder-2000" NAME="Inder 2000" TYPE="JOURNAL_ARTICLE">
<AU>Inder TE, Volpe JJ</AU>
<TI>Mechanisms of perinatal brain injury</TI>
<SO>Seminars in Neonatology</SO>
<YR>2000</YR>
<VL>5</VL>
<PG>3-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacobs-2007" MODIFIED="2012-04-19 14:41:05 -0400" MODIFIED_BY="[Empty name]" NAME="Jacobs 2007" TYPE="COCHRANE_REVIEW">
<AU>Jacobs S, Hunt R, Tarnow-Mordi W, Inder T, Davis P</AU>
<TI>Cooling for newborns with hypoxic ischaemic encephalopathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2012-04-19 14:41:05 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-19 14:41:05 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003311.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1991" NAME="Johnson 1991" TYPE="JOURNAL_ARTICLE">
<AU>Johnson WD, Kayser KL, Brenowitz JB, Saedi SF</AU>
<TI>A randomized controlled trial of allopurinol in coronary bypass surgery</TI>
<SO>American Heart Journal</SO>
<YR>1991</YR>
<VL>121</VL>
<PG>20-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kecskes-2005" MODIFIED="2012-04-19 14:42:57 -0400" MODIFIED_BY="[Empty name]" NAME="Kecskes 2005" TYPE="COCHRANE_REVIEW">
<AU>Kecskes Z, Healy G, Jensen A</AU>
<TI>Fluid restriction for term infants with hypoxic-ischaemic encephalopathy following perinatal asphyxia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2012-04-19 14:42:57 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-19 14:42:57 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004337.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kumar-1996" NAME="Kumar 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kumar A, Edward N, White MI, Johnston PW, Catto GR</AU>
<TI>Allopurinol, erythema multiforme, and renal insufficiency</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>312</VL>
<PG>173-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kurinczuk-2010" MODIFIED="2012-05-07 17:15:45 -0400" MODIFIED_BY="[Empty name]" NAME="Kurinczuk 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kurinczuk JJ, White-Koning M, Badawi N</AU>
<TI>Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy</TI>
<SO>Early Human Development</SO>
<YR>2010</YR>
<VL>86</VL>
<PG>329-38</PG>
<IDENTIFIERS MODIFIED="2012-05-03 10:42:07 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20554402"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-MacLennan-1999" MODIFIED="2007-12-13 11:10:58 -0500" MODIFIED_BY="[Empty name]" NAME="MacLennan 1999" TYPE="JOURNAL_ARTICLE">
<AU>MacLennan A</AU>
<TI>A template for defining a causal relation between acute intrapartum events and cerebral palsy: international consensus statement</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>1054-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marro-1997" MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]" NAME="Marro 1997" TYPE="JOURNAL_ARTICLE">
<AU>Marro PJ, Baumgart S, Delivoria-Papadopoulos M, Zirin S, Corcoran L, McGaurn SP, et al</AU>
<TI>Purine metabolism and inhibition of xanthine oxidase in severely hypoxic neonates going onto extracorporeal membrane oxygenation</TI>
<SO>Pediatric Research</SO>
<YR>1997</YR>
<VL>41</VL>
<PG>513-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGaurn-1994" MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]" NAME="McGaurn 1994" TYPE="JOURNAL_ARTICLE">
<AU>McGaurn SP, Davis LE, Krawczeniuk MM, Murphy JD, Jacobs ML, Norwood WI, et al</AU>
<TI>The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>94</VL>
<PG>820-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGuire-2004" MODIFIED="2012-04-19 14:39:19 -0400" MODIFIED_BY="[Empty name]" NAME="McGuire 2004" TYPE="COCHRANE_REVIEW">
<AU>McGuire W, Fowlie PW, Evans DJ</AU>
<TI>Naloxone for preventing morbidity and mortality in newborn infants of greater than 34 weeks' gestation with suspected perinatal asphyxia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2012-04-19 14:39:19 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-19 14:39:19 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003955.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pacher-2006" NAME="Pacher 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pacher P, Nivorozhkin A, Szabo C</AU>
<TI>Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol</TI>
<SO>Pharmacological Reviews</SO>
<YR>2006</YR>
<VL>58</VL>
<PG>87-114</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmer-1990" NAME="Palmer 1990" TYPE="JOURNAL_ARTICLE">
<AU>Palmer C, Vannucci RC, Towfighi J</AU>
<TI>Reduction of perinatal hypoxic-ischemic brain damage with allopurinol</TI>
<SO>Pediatric Research</SO>
<YR>1990</YR>
<VL>27</VL>
<PG>332-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmer-1991" MODIFIED="2012-05-15 13:10:50 -0400" MODIFIED_BY="Anne Lawson" NAME="Palmer 1991" TYPE="JOURNAL_ARTICLE">
<AU>Palmer C, Smith MB, Williams GD</AU>
<TI>Allopurinol preserves cerebral energy metabolism during perinatal hypoxic-ischemic injury and reduces brain damage in a dose dependent manner</TI>
<SO>Journal of Cerebral Blood Flow and Metabolism</SO>
<YR>1991</YR>
<VL>11</VL>
<PG>S144-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmer-1993" NAME="Palmer 1993" TYPE="JOURNAL_ARTICLE">
<AU>Palmer C, Towfighi J, Roberts RL, Heitjan DF</AU>
<TI>Allopurinol administered after inducing hypoxia-ischemia reduces brain injury in 7-day-old rats</TI>
<SO>Pediatric Research</SO>
<YR>1993</YR>
<VL>33</VL>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perlman-2006" NAME="Perlman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Perlman JM</AU>
<TI>Intervention strategies for neonatal hypoxic-ischemic cerebral injury</TI>
<SO>Clinical Therapeutics</SO>
<YR>2006</YR>
<VL>28</VL>
<PG>1353-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-04-19 14:17:03 -0400" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robertson-2012" MODIFIED="2012-05-07 17:16:01 -0400" MODIFIED_BY="[Empty name]" NAME="Robertson 2012" TYPE="JOURNAL_ARTICLE">
<AU>Robertson NJ, Tan S, Groenendaal F, van Bel F, Juul SE, Bennet L, et al</AU>
<TI>Which neuroprotective agents are ready for bench to bedside translation in the newborn infant?</TI>
<SO>The Journal of Pediatrics</SO>
<YR>2012</YR>
<VL>160</VL>
<PG>544-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22325255"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Roth-1997" MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]" NAME="Roth 1997" TYPE="JOURNAL_ARTICLE">
<AU>Roth SC, Baudin J, Cady E, Johal K, Townsend JP, Wyatt JS, et al</AU>
<TI>Relation of deranged neonatal cerebral oxidative metabolism with neurodevelopmental outcome and head circumference at 4 years</TI>
<SO>Developmental Medicine and Child Neurology</SO>
<YR>1997</YR>
<VL>39</VL>
<PG>718-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sarnat-1976" MODIFIED="2007-12-13 11:12:45 -0500" MODIFIED_BY="[Empty name]" NAME="Sarnat 1976" TYPE="JOURNAL_ARTICLE">
<AU>Sarnat HB, Sarnat MS</AU>
<TI>Neonatal encephalopathy following fetal distress</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1976</YR>
<VL>33</VL>
<PG>696-705</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sisto-1995" NAME="Sisto 1995" TYPE="JOURNAL_ARTICLE">
<AU>Sisto T, Paajanen H, Metsa-Ketela T, Harmoinen A, Nordback I, Tarkka M</AU>
<TI>Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1995</YR>
<VL>59</VL>
<PG>1519-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Bel-1998" MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]" NAME="Van Bel 1998" TYPE="JOURNAL_ARTICLE">
<AU>Van Bel F, Shadid M, Moison RM, Dorrepaal CA, Fontijn J, Monteiro L, et al</AU>
<TI>Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>185-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Kesteren-2006" NAME="van Kesteren 2006" TYPE="JOURNAL_ARTICLE">
<AU>van Kesteren C, Benders MJ, Groenendaal F, van Bel F, Ververs FF, Rademaker CM</AU>
<TI>Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia</TI>
<SO>Therapeutic Drug Monitor</SO>
<YR>2006</YR>
<VL>28</VL>
<PG>339-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vannucci-1997" NAME="Vannucci 1997" TYPE="JOURNAL_ARTICLE">
<AU>Vannucci RC, Perlman JM</AU>
<TI>Current and potentially new management strategies for perinatal hypoxic-ischemic encephalopathy</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>100</VL>
<PG>1004-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vazquez_x002d_Mellado-2001" NAME="Vazquez-Mellado 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R</AU>
<TI>Relation between adverse events associated with allopurinol and renal function in patients with gout</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2001</YR>
<VL>60</VL>
<PG>981-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warner-2004" MODIFIED="2008-02-20 12:02:04 -0500" MODIFIED_BY="[Empty name]" NAME="Warner 2004" TYPE="JOURNAL_ARTICLE">
<AU>Warner DS, Sheng H, Batinic-Haberle I</AU>
<TI>Oxidants, antioxidants and the ischemic brain</TI>
<SO>Journal of Experimental Biology</SO>
<YR>2004</YR>
<VL>207</VL>
<PG>3221-312</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-04-19 14:09:22 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Chaudhari-2008" MODIFIED="2012-04-19 14:09:22 -0400" MODIFIED_BY="[Empty name]" NAME="Chaudhari 2008" TYPE="COCHRANE_REVIEW">
<AU>Chaudhari T, McGuire W</AU>
<TI>Allopurinol for preventing mortality and morbidity in newborn infants with suspected hypoxic-ischaemic encephalopathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-04-19 14:09:19 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-19 14:09:19 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006817.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-06-12 22:02:34 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-06-12 22:02:34 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-06-11 15:38:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benders-2006">
<CHAR_METHODS MODIFIED="2012-04-04 10:56:39 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-15 13:08:54 -0400" MODIFIED_BY="[Empty name]">
<P>Term newborn infants with evidence of perinatal asphyxia and severe neonatal encephalopathy (burst suppression pattern, or worse, on aEEG)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-15 13:09:00 -0400" MODIFIED_BY="[Empty name]">
<P>Allopurinol (40 mg/kg intravenously) in 2 doses, within 4 hours after birth and 12 hours later (n = 17) versus placebo control (n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-15 13:09:11 -0400" MODIFIED_BY="[Empty name]">
<P>Mortality, changes in aEEG, abnormalities on brain ultrasound, and magnetic resonance imaging abnormal findings in surviving infants at discharge, and severe disability at 4 to 8 years defined as non-ambulant cerebral palsy (Gross Motor Function Classification System levels III to V), epilepsy not responding to treatment, blindness, deafness with or without a full-scale intelligence quotient &lt; 70</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-11 15:38:18 -0400" MODIFIED_BY="[Empty name]">
<P>The trial was stopped earlier than planned when an interim analysis had not detected any statistically significant effects.</P>
<P>Follow up of this trial and the trial of van Bel 1998 was reported by Kaandorp 2012.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-12 22:02:01 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gunes-2007">
<CHAR_METHODS MODIFIED="2012-06-12 22:01:28 -0400" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-12 22:01:31 -0400" MODIFIED_BY="[Empty name]">
<P>Sixty asphyxiated infants were divided randomly into two groups</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-12 22:01:35 -0400" MODIFIED_BY="[Empty name]">
<P>Group I infants (n = 30) received allopurinol (40 mg/kg/day, 3 days) within 2 hours after birth. Group II infants (n = 30) received a placebo. Twenty healthy neonates served as control subjects</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-12 22:01:51 -0400" MODIFIED_BY="[Empty name]">
<P>Cerebrospinal fluid and serum nitric oxide levels were measured within 0-24 hours and 72-96 hours after birth</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-12 22:02:01 -0400" MODIFIED_BY="[Empty name]">
<P>Both serum and cerebrospinal fluid concentrations of nitric oxide were higher in severely asphyxiated infants (40.86 +/- 8.97, 17.3 +/- 3.63 micromol/L, respectively) but lower in mildly asphyxiated infants (25.85 +/- 3.57, 5.70 +/- 2.56 micromol/L, respectively) than in moderately asphyxiated infants (35.86 +/- 5.38, 11.06 +/- 3.37 micromol/L, respectively) within the first 0-24 hours after birth. Serum nitric oxide levels in control subjects were lower than those of moderately and severely asphyxiated infants. Serum nitric oxide levels of Group I infants within 72-96 hours after birth decreased significantly from their corresponding levels within 0-24 hours after birth. The asphyxiated newborns treated with allopurinol had better neurologic and neurodevelopmental outcome at 12 or more months of age</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-12 22:02:34 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Bel-1998">
<CHAR_METHODS MODIFIED="2012-06-12 22:02:06 -0400" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-12 22:02:09 -0400" MODIFIED_BY="[Empty name]">
<P>Severely asphyxiated newborns; Eleven infants received 40 mg/kg ALLO intravenously, and 11 infants served as controls (CONT)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-11 15:43:44 -0400" MODIFIED_BY="[Empty name]">
<P>High-dose allopurinol (ALLO; 40 mg/kg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-12 22:02:25 -0400" MODIFIED_BY="[Empty name]">
<P>Effect on free radical status in severely asphyxiated newborns and on post-asphyxial cerebral perfusion and electrical brain activity</P>
<P>Free radical status was assessed by serial plasma determination of non protein-bound iron (microM), antioxidative capacity, and malondialdehyde (MDA; microM). Cerebral perfusion was investigated by monitoring changes in cerebral blood volume (delta CBV; mL/100 g brain tissue) with near infrared spectroscopy; electrocortical brain activity (ECBA) was assessed in microvolts by cerebral function monitor</P>
<P>Plasma non protein-bound iron, antioxidative capacity, and MDA were measured before 4 hours, between 16 and 20 hours, and at the second and third days of age. Changes in CBV and ECBA were monitored between 4 and 8, 16 and 20, 58 and 62, and 104 and 110 hours of age</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-12 22:02:34 -0400" MODIFIED_BY="[Empty name]">
<P>Six CONT and two ALLO infants died after neurologic deterioration. No toxic side effects of ALLO were detected. Nonprotein-bound iron (mean +/- SEM) in the CONT group showed an initial rise (18.7 +/- 4.6 microM to 21.3 +/- 3.4 microM) but dropped to 7.4 +/- 3.5 microM at day 3; in the ALLO group it dropped from 15.5 +/- 4.6 microM to 0 microM at day 3. Uric acid was significantly lower in ALLO-treated infants from 16 hours of life on. MDA remained stable in the ALLO group, but increased in the CONT group at 8 to 16 hours versus &lt; 4 hours (mean +/- SEM; 0.83 +/- 0.31 microM vs 0.50 +/- 0.14 microM). During 4 to 8 hours, delta CBV-CONT showed a larger drop than delta CBV-ALLO from baseline. During the subsequent registrations CBV remained stable in both groups. ECBA-CONT decreased, but ECBA-ALLO remained stable during 4 to 8 hours of age. Neonates who died had the largest drops in CBV and ECBA</P>
<P>Follow up of this trial and the trial of Bender 2006 was reported by Kaandorp 2012</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>aEEG: amplitude-integrated electroencephalogram; SD: standard deviation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-05-15 06:44:35 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-05-15 06:44:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaandorp-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-15 06:44:31 -0400" MODIFIED_BY="[Empty name]">
<P>Protocol for a randomised controlled trial of<I> </I>antenatal<I> </I>allopurinol in mothers with evidence of fetal hypoxia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-15 06:44:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Torrance-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-15 06:44:35 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial of antenatal<I> </I>allopurinol in mothers with evidence of fetal hypoxia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-15 13:11:34 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benders-2006">
<DESCRIPTION>
<P>Computer-generated sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-03 10:33:07 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gunes-2007">
<DESCRIPTION>
<P>Sequence generated using random number tables by person not involved with trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-03 10:34:55 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Bel-1998">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-05-03 10:35:16 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-03 10:32:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benders-2006">
<DESCRIPTION>
<P>Randomisation in central pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-03 10:33:07 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gunes-2007">
<DESCRIPTION>
<P>Sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-03 10:35:16 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Bel-1998">
<DESCRIPTION>
<P>Sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-04-19 14:23:44 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-19 14:23:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benders-2006">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-19 14:23:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gunes-2007">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-19 14:23:44 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-Bel-1998">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-05-15 13:09:45 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-15 13:09:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benders-2006">
<DESCRIPTION>
<P>1 infant who was diagnosed with a (probably genetic) condition associated with neurodevelopmental delay was excluded from analyses in the trial reports but re-included in intention-to-treat analyses in this review</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-15 13:09:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gunes-2007">
<DESCRIPTION>
<P>2 infants in each group were lost to long-term follow-up. All had mild neonatal encephalopathy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-15 13:09:45 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Bel-1998">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-04-07 05:23:48 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-04-07 05:23:48 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Allopurinol versus control (placebo or no drug)</NAME>
<DICH_OUTCOME CHI2="5.088574265508146" CI_END="1.260399080268479" CI_START="0.6633715080116653" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9143920595533499" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" I2="21.39251996157003" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.10050807759108443" LOG_CI_START="-0.17824318548316279" LOG_EFFECT_SIZE="-0.038867553946039156" METHOD="MH" MODIFIED="2012-04-07 05:23:48 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.27832945596034686" P_Q="0.7555468494588261" P_Z="0.5846718843375168" Q="0.09692877380125312" RANDOM="NO" SCALE="12.912976671627678" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="78" TOTAL_2="77" WEIGHT="200.0" Z="0.5465733504577066">
<NAME>Death during the neonatal period and infancy</NAME>
<GROUP_LABEL_1>Allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours allopurinol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.369433872558105" CI_END="1.3752158752734998" CI_START="0.5577443947477143" DF="2" EFFECT_SIZE="0.8757961783439491" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="40.64284756294737" ID="CMP-001.01.01" LOG_CI_END="0.13837087713440957" LOG_CI_START="-0.2535647856203141" LOG_EFFECT_SIZE="-0.05759695424295227" MODIFIED="2012-04-04 08:09:42 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1854971642192399" P_Z="0.5645790204984051" STUDIES="3" TAU2="0.0" TOTAL_1="58" TOTAL_2="56" WEIGHT="100.0" Z="0.5760535039958027">
<NAME>All infants</NAME>
<DICH_DATA CI_END="1.789073335580655" CI_START="0.7354332091756568" EFFECT_SIZE="1.1470588235294117" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.25262814301859354" LOG_CI_START="-0.13345676305010548" LOG_EFFECT_SIZE="0.05958568998424405" ORDER="1" O_E="0.0" SE="0.22678818497586148" STUDY_ID="STD-Benders-2006" TOTAL_1="17" TOTAL_2="15" VAR="0.05143288084464556" WEIGHT="54.14012738853503"/>
<DICH_DATA CI_END="4.5639184979939795" CI_START="0.21910996010107084" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.7745966692414834" STUDY_ID="STD-Gunes-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.6" WEIGHT="15.286624203821656"/>
<DICH_DATA CI_END="1.3049065853133626" CI_START="0.08514870900465929" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.1155794228351965" LOG_CI_START="-1.0698219322745213" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-04-04 04:56:26 -0400" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.6963106238227913" STUDY_ID="STD-van-Bel-1998" TOTAL_1="11" TOTAL_2="11" VAR="0.48484848484848475" WEIGHT="30.573248407643312"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6731011551261217" CI_END="1.5130452919446342" CI_START="0.6201373080217499" DF="1" EFFECT_SIZE="0.9686567164179104" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="40.230750726807194" ID="CMP-001.01.02" LOG_CI_END="0.1798519285170545" LOG_CI_START="-0.2075121403179689" LOG_EFFECT_SIZE="-0.013830105900457223" MODIFIED="2012-04-04 08:12:16 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19584375084827066" P_Z="0.8886966044494927" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="99.99999999999999" Z="0.13995365935096885">
<NAME>Infants with severe encephalopathy</NAME>
<DICH_DATA CI_END="1.789073335580655" CI_START="0.7354332091756568" EFFECT_SIZE="1.1470588235294117" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.25262814301859354" LOG_CI_START="-0.13345676305010548" LOG_EFFECT_SIZE="0.05958568998424405" MODIFIED="2012-04-04 08:12:16 -0400" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.22678818497586148" STUDY_ID="STD-Benders-2006" TOTAL_1="17" TOTAL_2="15" VAR="0.05143288084464556" WEIGHT="76.11940298507461"/>
<DICH_DATA CI_END="2.061703921857245" CI_START="0.07760571161734377" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.31422629705994987" LOG_CI_START="-1.110106314404025" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-04-04 08:10:51 -0400" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-van-Bel-1998" TOTAL_1="3" TOTAL_2="6" VAR="0.7000000000000001" WEIGHT="23.88059701492537"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.220054289269759" CI_END="1.0544965668040807" CI_START="0.6432279857688141" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8235785953177259" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.02304517011583686" LOG_CI_START="-0.1916350684253973" LOG_EFFECT_SIZE="-0.08429494915478021" METHOD="MH" MODIFIED="2012-04-04 12:01:57 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6953595067494492" P_Q="0.47226455714826654" P_Z="0.12376195124832069" Q="0.516672658721786" RANDOM="NO" SCALE="6.31949566069344" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="76" TOTAL_2="75" WEIGHT="200.0" Z="1.539173475347812">
<NAME>Death or severe neurodevelopmental disability</NAME>
<GROUP_LABEL_1>Allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours allopurinol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8952827957976623" CI_END="1.0813356004908492" CI_START="0.5567753824536182" DF="2" EFFECT_SIZE="0.7759259259259259" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="33" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.03396050137398733" LOG_CI_START="-0.2543199750873337" LOG_EFFECT_SIZE="-0.1101797368566732" MODIFIED="2012-04-04 08:13:33 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3876543364357118" P_Z="0.1340859607220567" STUDIES="3" TAU2="0.0" TOTAL_1="56" TOTAL_2="54" WEIGHT="100.0" Z="1.4981820393525955">
<NAME>All infants</NAME>
<DICH_DATA CI_END="1.3775803303246474" CI_START="0.6632724441187616" EFFECT_SIZE="0.9558823529411765" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.1391169331133162" LOG_CI_START="-0.17830804524007768" LOG_EFFECT_SIZE="-0.019595556063380724" MODIFIED="2012-04-04 05:05:56 -0400" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.18645700356376768" STUDY_ID="STD-Benders-2006" TOTAL_1="17" TOTAL_2="15" VAR="0.03476621417797887" WEIGHT="37.77777777777778"/>
<DICH_DATA CI_END="1.3035756418003308" CI_START="0.4125405235672157" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.11513623678041919" LOG_CI_START="-0.38453338457533165" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="4" O_E="0.0" SE="0.2935084089888843" STUDY_ID="STD-Gunes-2007" TOTAL_1="28" TOTAL_2="28" VAR="0.08614718614718617" WEIGHT="44.44444444444444"/>
<DICH_DATA CI_END="1.5104711327765359" CI_START="0.1655112729896744" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.17911242971147984" LOG_CI_START="-0.7811724210394423" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-04-04 05:05:20 -0400" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.5640760748177661" STUDY_ID="STD-van-Bel-1998" TOTAL_1="11" TOTAL_2="11" VAR="0.3181818181818181" WEIGHT="17.77777777777778"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13716625897717594" CI_END="1.2972932765667" CI_START="0.6575159490154774" DF="1" EFFECT_SIZE="0.9235751295336789" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.11303816729189949" LOG_CI_START="-0.18209370825964044" LOG_EFFECT_SIZE="-0.03452777048387051" MODIFIED="2012-04-04 08:14:46 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7111146503226884" P_Z="0.6465241269992422" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.00000000000001" Z="0.45859625625584666">
<NAME>Infants with severe encephalopathy</NAME>
<DICH_DATA CI_END="1.3775803303246474" CI_START="0.6632724441187616" EFFECT_SIZE="0.9558823529411765" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.1391169331133162" LOG_CI_START="-0.17830804524007768" LOG_EFFECT_SIZE="-0.019595556063380724" MODIFIED="2012-04-04 08:14:25 -0400" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.18645700356376768" STUDY_ID="STD-Benders-2006" TOTAL_1="17" TOTAL_2="15" VAR="0.03476621417797887" WEIGHT="79.27461139896374"/>
<DICH_DATA CI_END="1.9220243686433105" CI_START="0.33298225061098136" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2837588896281722" LOG_CI_START="-0.477578915644285" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2012-04-04 08:14:46 -0400" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-van-Bel-1998" TOTAL_1="3" TOTAL_2="6" VAR="0.19999999999999998" WEIGHT="20.725388601036272"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6190599716387627" CI_END="1.267183147536382" CI_START="0.2752172787173071" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5905511811023622" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.10283938853469908" LOG_CI_START="-0.5603243036632128" LOG_EFFECT_SIZE="-0.22874245756425685" METHOD="MH" MODIFIED="2012-04-04 12:20:22 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7337918089425357" P_Q="1.0" P_Z="0.17634799196254738" Q="0.0" RANDOM="NO" SCALE="59.32911507186519" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0" Z="1.35208541672492">
<NAME>Severe quadriplegia in surviving infants</NAME>
<GROUP_LABEL_1>Allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours allopurinol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.815756983267709" CI_START="0.020471465571733422" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8929710473245055" LOG_CI_START="-1.6888510646685806" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-04-04 05:08:28 -0400" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="1.51657508881031" STUDY_ID="STD-Benders-2006" TOTAL_1="4" TOTAL_2="5" VAR="2.3" WEIGHT="10.498687664041993"/>
<DICH_DATA CI_END="1.2458124628441516" CI_START="0.23881657153902142" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.09545267114991443" LOG_CI_START="-0.6219355406990773" LOG_EFFECT_SIZE="-0.26324143477458145" ORDER="5" O_E="0.0" SE="0.4213973867690182" STUDY_ID="STD-Gunes-2007" TOTAL_1="25" TOTAL_2="25" VAR="0.17757575757575755" WEIGHT="84.68941382327209"/>
<DICH_DATA CI_END="37.49283370139692" CI_START="0.08641651430788716" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.573948265558182" LOG_CI_START="-1.0634032553515698" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2012-04-04 05:08:53 -0400" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="1.5491933384829668" STUDY_ID="STD-van-Bel-1998" TOTAL_1="9" TOTAL_2="5" VAR="2.4" WEIGHT="4.811898512685914"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1970545082793844" CI_END="1.1642849517434646" CI_START="0.7450068907740972" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9313432835820895" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.06605928428694702" LOG_CI_START="-0.12783971032375196" LOG_EFFECT_SIZE="-0.030890213018402467" METHOD="MH" MODIFIED="2012-04-04 05:09:29 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5496207320056004" P_Q="1.0" P_Z="0.5323077798733779" Q="0.0" RANDOM="NO" SCALE="3.1627503055633674" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="56" WEIGHT="100.0" Z="0.6244870440137751">
<NAME>Seizures during the neonatal period</NAME>
<GROUP_LABEL_1>Allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours allopurinol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2073305629171263" CI_START="0.84225262774265" EFFECT_SIZE="1.0084033613445378" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.08182619470024485" LOG_CI_START="-0.07455762539005677" LOG_EFFECT_SIZE="0.0036342846550940556" ORDER="6" O_E="0.0" SE="0.09186063003343736" STUDY_ID="STD-Benders-2006" TOTAL_1="17" TOTAL_2="15" VAR="0.008438375350140054" WEIGHT="35.52238805970149"/>
<DICH_DATA CI_END="1.3776821067264202" CI_START="0.6550858108656689" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.13914901784622846" LOG_CI_START="-0.18370180726853297" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="7" O_E="0.0" SE="0.18964417280976958" STUDY_ID="STD-Gunes-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.03596491228070175" WEIGHT="47.76119402985074"/>
<DICH_DATA CI_END="1.5683978900914195" CI_START="0.3253027084873942" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.19545624938800707" LOG_CI_START="-0.48771232074448306" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="8" O_E="0.0" SE="0.4012965998347868" STUDY_ID="STD-van-Bel-1998" TOTAL_1="11" TOTAL_2="11" VAR="0.161038961038961" WEIGHT="16.71641791044776"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7317058604039881" CI_END="1.7011613239497132" CI_START="0.874322741949375" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2195753495598138" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.23074550043150002" LOG_CI_START="-0.05832822506045927" LOG_EFFECT_SIZE="0.08620863768552037" METHOD="MH" MODIFIED="2012-04-04 12:24:57 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3923308383854057" P_Q="0.4237566551479647" P_Z="0.24239742877128556" Q="0.639874049626119" RANDOM="NO" SCALE="7.648878931208616" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="19" WEIGHT="200.0" Z="1.1690154456779382">
<NAME>Abnormalities on brain imaging</NAME>
<GROUP_LABEL_1>Allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours allopurinol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5526736677986868" CI_START="0.812222822791454" DF="0" EFFECT_SIZE="1.1229946524064172" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.19108018775260294" LOG_CI_START="-0.09032481135776232" LOG_EFFECT_SIZE="0.05037768819742032" NO="1" P_CHI2="1.0" P_Z="0.48283298272626163" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="0.7017533789625947">
<NAME>Cranial ultrasound</NAME>
<DICH_DATA CI_END="1.552673667798687" CI_START="0.8122228227914539" EFFECT_SIZE="1.1229946524064172" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.191080187752603" LOG_CI_START="-0.0903248113577624" LOG_EFFECT_SIZE="0.05037768819742032" ORDER="9" O_E="0.0" SE="0.16529868945463985" STUDY_ID="STD-Benders-2006" TOTAL_1="17" TOTAL_2="14" VAR="0.02732365673542146" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.309769635732656" CI_START="0.5571716881850607" DF="0" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.8000135038152265" LOG_CI_START="-0.2540109596877512" LOG_EFFECT_SIZE="0.27300127206373764" NO="2" P_CHI2="1.0" P_Z="0.3099654425886337" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="5" WEIGHT="100.0" Z="1.015294577130154">
<NAME>Magnetic resonance imaging (surviving infants)</NAME>
<DICH_DATA CI_END="6.309769635732655" CI_START="0.5571716881850608" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8000135038152264" LOG_CI_START="-0.25401095968775117" LOG_EFFECT_SIZE="0.27300127206373764" ORDER="10" O_E="0.0" SE="0.6191391873668902" STUDY_ID="STD-Benders-2006" TOTAL_1="4" TOTAL_2="5" VAR="0.38333333333333325" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-05-15 13:11:35 -0400" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-04-07 05:23:49 -0400" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Allopurinol versus control (placebo or no drug), outcome: 1.1 Death during the neonatal period and infancy.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-04-04 12:01:58 -0400" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Allopurinol versus control (placebo or no drug), outcome: 1.2 Death or severe neurodevelopmental disability.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArEAAAFgCAMAAACbjtEIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///9BjlLGAAA1RElEQVR42u19C3Acx3nmj8fO7AME0AvAIigxJgicnXJk3QmgCOLBUryQLdNyyilHdqXimEfrquxcJY4vZZ0T+1KR7SRnyylW7CvHeiR1ik5xHCVyYimmpSQCSjKwILkiIUdRlJKNlyiRkARgGgCxWOwOgL2ex85rZ2ZnF7OLBfB/fOxsP/7+p+ebv//p+be7hgACsYtQi12AQMYiEMhYBKL6GJuIxWIiQCwm/XVGXqZraSNGwxzfIFoSW0MlStsW2KkG+FCboTXjkZKX0zpSKaWcNOW40JiTpixP1Pu3/JrWhaqIsU+0A6ysQwfMsL/OxWasea6ljdz8i7prD/bMb5hTTxyeKUna9tABI1vPTU5v6Cejt5vLU7++dtNM/jlXDkybzdXYHztpyvLerqSmVWVjBUgA1b7dy/ON0i37CB8W5TtXtr2RoPKZCgWjuTJesT6wFBVGUgBZnpNFkwifCrADRS40csVI2z5OwpZ0Mq3hgHSKDOIpXjTkiSGeC0V5RUGmHs817dCVCSmajkaYRU3ImgY/nTDkJcJcIJzicpoq/bsPGPtZmIfP5L40TYTPHZOu0OciJ+r1Mk9fUz5vaOhf08t4w6/BdUX00LmIXG0rPPA5RpERRW7zsUjoWCUpm1K6f/XEW40nDrCDxQMjqwFDXqOQTvatpRUFoenYuUhP885cmVGokz7e3/vma323S4Q9cPrPjhvybl/MrJ0gmZymuf7d64wVXhkLjU3mjEwaphrZfwCzk8DrhW6OKp/PzrNbez1XxhsmQal8DLqnWF3mX8zDo7rcFExNw20V9A/vurgiHWzBjRtPSOp8vD8cMOalDjf+FsvVOqRxium4I57sfReeVzQ99MwTkgoH+vsCxrzUpXsbYTNXXuvfvc7YEHDsz1+p37IQPS53QjRqLJT7wu7wQb2MN8SZ36FYBVUm+3/AKJclj1bsdEe+MqYcNMT7bm2X3uSMja+b8ppv+cO/Z2epYhOOR3fmwox8ZRS6pIPlsf7HDkmabo3/Zi7vJSnv2fseaGCOjGZ1o+XTtJoYewMcjx2HM7rNFeAOaQZBgBpgFzCRX+NMrow3BOCAetKCYG/lhUp2yMlw7xflVudeHB5Yk8YNrm/UmLcGn3xVL36HpF7NjlyZkw0njsg25c2fDPdLmjbyJ3KaLkh5d8HrrxpJ5dC/e42xm/CTkXMQUb8FoXMCxqUr1cVGmFpos2Hm47ky3vCzsWbhx7EwM+QTnUy+ii7V8kotHjU6IGXH0vn/I/lA4bvrBPivEjEWxz5ozDsD7+rUh4a4SevKgp5PqZpuyDfNwsLonea8tEFTrpyaVhNjM/AW1MOGyp+ZS8m7Li1LKq5e3IBwzXUbLmllvKF9eOuGrwy/AbOXvpa8rFV7YuywKq072VOENB/AD0pPUsuJlfbzfyYPAoHeVkNeX/w/S50Rjt8kJcxeuit5eWmHrg13Utb05uWGC/I4FeBPtBryluJHJOcsMnajoqmxf31GTbVHwsSUx08EYpcwlsuKeJUQOuqrXcEMXiNEtfqxCAQyFoGMRSCQsQhECYwVGnhuKJKwxou6xDsmskMcHxE9lCyImAzbrNaQhxqjEXuFi5VrkRp2kCqCwMU4AcTYqbx89chQV5ErQmtOtPyh1VCatNVSSxSz3FA2AYJStplrBmiI5s6DlyZUfIhLlZUcLV3JRAPH3SuyTlGUDDwEEFFfjY2e4oYaEn4oaYiPPbS6dP2V9311wxIv6hIu+tcnv/uN1fd98HLhkgXRASMzDpGV1vhVFTMzUp3cNyky006NYuV6lHp9/cPT8HO/8Ehr+/lMrqKlpKGunAj/9/9x7aDkyUU0ibKO9nGlWpnaoaVvXf16+uH2iz+VCs6e3RAD11UuB66eem1R9CGslym5mvpB6Up+7/i/tWaX0pl3Dc+ygqfHhzfnvvmwnDPX/fq1L/X8kR9KGmzsF2ADQiPrgVyQI/snRoIEIBRrY/eN/NYtF7PaIBNdhPewGg/nSgM0nQqJkAgHm+XbMRzOxXRq0a2PqIGg9miNNbD/G2KtUnylYIxfbQtxXMS+phyLKceQihGOD436I1fWW473bItwXLDVkr0JH4Y4+7cJAeFejs8KSm/xRO6G1tCpqFzXiPGPwsa4q4Fr44IghAKiIMXpCpAIBfXYQh4WuiEDW5JOrPn2LahXbU3zYDB6ciTpz5DLZyDDuyopBsIgBPk2QelLMczrM/oZCE1CGg6CnPRoIAs/rwo7OBCOCiNrPnsFtdAtXW81XlRGfW9YkF4Ti/CY/MJdi0edvyobaLjVzJDshb7vwG0nfqjEpC++nhfTaY51tWLh/HE2phw/nxkKLx9jN7wev3q9b66p1zbislGOxZRjSJuezqz2PeaLXEVvOd5zlc+81n/dkn+aXZ0A65YMvNIx0RAeOiIltvSqt+P6SnotA5aXdfWn4dfcZ7/ng/3PHu0LBzqORSLHjkCs74dapCHUSG/sTzObkuTYJakVa8XQlJKzAT/1z0kc3YRN9+i1QPgE6egPzh9R+rL+RFiPnTujhBVsQEo2A+IZIT2t5ATh1TL4sSvj0HdfxBQhxcPkCwBvsgvzW/LNrcWjpmQf6nlrjdkpeIpp16j8kCDVkhfTaY51zfMgg9DC/vC3wVRKbkaLXx2AX994wvYWvU2PxVz7lcZGLd51e3INeqdqG++BrDk7/oq4NXZlbFPsH2tfh8kp5T0H650rcvaVgB7Vql/qV1onA0atzDpKH8+O37XGz0hyJplmvdA9q/MdukKSzvGxyInDEIoE2/ij3EPKKfgY2RfoE/sLKDkzvrY+PgNqX/IwpSsZhK4uqatqVht6P8+U7DnKd/DNPitpYGzg2sQ49N5uzB2U4k8hFN+Y2xifB2PMqpx9/Nplcw05vnQLjisnHc2P6WQFnOLlRhimutJiumt6FO6+W77mWvzqF+PpW3/P9qTlWEyFUOS9W9NavOv25Br0JrdsvaAHqapdBfUDXJQbaGH3cVYSuqnYQT3sdjBP5D8xJr5t1Mqso9yfwYHBuCSCSRyWOlvX7PWLyWgcIJk+PsVs2FJmen3m48nflu8e8DGy7xVoZv9clYzyAwO8dJ3lvhw0Knk2cT0dr4HkcGASHmRKfmx9Id0oW5Mx/5Q0zm5Fl669qMZHx2XvQGpIaikw+J8GOdXsm+JRo8vXJpjaY6AqJAdw1oGgeYZ1StJorkDCXfHo3w40D/xttBaeGBkxvZ69Y+7cxclV+xPQokaTcIX3SW6dSWresFvPbEs9+7PO/tVIQtUTFhLO53Z8PBMP5BkuE4QUH1+XRMlqjhujTKPJdCprcCo6uehkIKvo8i7/GNseF+Pt7kqK6fF4KgFqX8aNSgZWxWS2LufGAHTVB/rnZUJx8O4yMDYYi0afkoYfkC7WXKs8OHZJHtqP4Ljih1jiUYOxVPQfWY0z0HpEeWrsZOYnBRNa16qRknXQphS4o8s9AHUq3hufYrWOijFtckjSJ3T30utQZ1dDbUGyNLXw7gmf5JqkHsiTGmC2ZZ79GWRHQeicU4Ty0Gn4zU2e7bt/8BtWw2XhxeMDF8KD9YrEkNSPHVqZ8KdFwqxGiJ8LyZGn6VchLp6Rc8bWhVQs4pdbMBgooGRLf/jcYCzXl+ycj2hlQnxbdDDIdG1VLnMqBONzMsOC8d8XorGwz4y9fjHJfTnxnBwvSuP3SJpvXFj9ltTeGIy3yz6MOR71x4kPB+5ILEFffJVTTNPa+AjQ82cJqD8IkWI6Ly0BHb/+I6W51YuLLn4stKxDoIXV6okkTPGrz188cvCC7VVRYzGlGNLQ+PJHfZKr6i3Fe4bjkWfynpHGgA9AgIexV6U+OXLxOflJ82KKSKOTAjVWVMd98OW8dsZMUxp/d55Sfqhtpjv5zgvPw8b5r9VqZf7p9UhqgsJK3ZGmSzOsKLRDKNwj6zK80d407FfcbL1NbJTpUUw8dl644/zxVrUvF/m1Oq1MpHY5+UkBwt9duXWYebejdfMQPCJPaSwsffFgMvGcHxp6iTYU4FD/SwueRXLh6cnfu2g33bLHY1354Ez6ExeKmcJpu77uS5myYu5oypcyPsELY/lsbbgIx3n0A5sQCM/bjuB7OnYwmtqsqVsOFFEjYttNZoQj8zt7Wg1Pn/SlTAUZi0AgEHsCv1L5JuvRxiK2gcrTB6MNEbsLyFjEbmZsRJksHgtznLbMqpomRz22GRZ31SeWm09xlrnh0TD2LKL8jBXDvcrB+zdfazrebE6DGwBMS1zpb0XW0m++YZZ63wnsWUT5GautS5NKt7+qTp1qaez7RdMygkq8ayhI+EG4O6rGpirrusqxofpaowhEeRibeF0/7lTftutpm/BMfgzd/2joT5ljU6V1XeXYUG2tUQSiTIxdbdEd0SSEzWmJvpqTNX3WV18z8yqL12rV2NRncynaWqMIRNnnCtqGBics5PwgXGB/Oi0FtUhQ8gdqbOrxXMpDubVGEYhyM1ZYqT1nDQbagN5YL/w3Jzn5samfyq01ikCUlbHsiepxOBACS2CkCD8Z+TJ8x1mOMTZVig0N3/30Ti3Qi9jDsP2t3O/IPykxRQYK7fBWIAgbwt32csLjWx89pn2TYkOXbz5ZU3dgHbsY4SswdguxDcQqH/CMb2kRe2GuAIFAxiIQyFgEMhaBQMYiEMhYxH4FzsciSsGK+tlY8ZaN77zkFQltGUydeE2VCrYffkFpvLBQSlzPoUS5WimbYkpdQ5NaBxCXPgNzs9ZOkyo755ovhzGXwv4wPqa3tAQKdbTN5WT/bD98I6yxpYLlNNb6JJcausbh7IlVmPyXEg8dl9eFSlNuucbzM+USCvuPsRbbQahuMQyJBhPgeFV8JCzxZjapdsW83S3e5Kql7EWSwmNQUSCuyST/TCtnVPNWOvyBU0bZF6qqdzEAOXMh39TmRPdr5OcARYot55E9xZVy9x1smiyeww6dptkLAhXnqQcaVj6uoN46BBKbi2occEhhgqik9hll89O86Opwj1p0IgqxpbGJFqEvdek0s7NlrwChAPvnAdrWj6VuHl3hHipP75XlNtimobfolBt8SBG3rUJvzy6BnQI+PzjsRj+2gNdmtDhV11NFK7T9M7AdZuh27waEPWoLPCObvtC8vIoRlu4ow2n5dKLV2CmF0ajgl3fYxqqjk3nUV4ctQyIxzB3Kh7r/Vja3qly+GvU0e2zfujmVEj1BOSYFBVJi22lOuVYXpJwdXrXAd17VBhejT0mJFcsG/A0CouSxfp+8QIB6ZEiVgZT4kLZfBku0sQhkLAKBXgFih5ELL9yB+EK0sYi9Y2M9TuzZhcMWEZha7EMwMX54VMqzXOqudgGpebrRYuNjc/3mEB9rDDu0torxsV5fUNuGw3oPTC2WsKYPj0p5lwtkG1LzdNODWrzGx6r95hAfq0Xe2mmO8bFyJxEjF6ntTwuIuzH028JSw4czSKlyfZVa8iBCvChr/ULKYxxsUWdb6PuV7656t4tESTE/LSjPOxdSpr7wFvla5N1UbFh54aI0P7CrfLQgXp68TIViOxwfa72AxPGUqjK4jZbyjp14eflZnNRi42NB819LsIr77i17fd4FpA6Dxe6Ityg2VpRsQ6r9YxcUFx9r7Pnif8pA9lFgrKNX4DYwu0XF7njXUVJpqVQLgKfEmFBUfGzBOQWKwUpOjCUGU0LzupWS6iGnf4SlpPR8/RcH2lN+yV3jUI9sI5bLXzRWI2O1gT/3Sw5TaoGo2B0nrEmpYnxO9+lYz1Kp+ZHVa3ysnR524bB5DMX4WETVjxUYHwv4lrYaKVvRanvyyQtRSWB8LNpYBDIWgUDGIhDIWMR+fPKyBL6aX3uVdeFYqxreJvsp8VWuq1TrkrUlrh/rFh9rtyquMT7WsPSUb30vR7007lrG2q8qa10wtdzrP3ldP7bYSR6P68e6LQqzvfVj9TU5bONj7VbFzVu3TyH0/ouPzfW3afFYB2tEK90/XtePLUUxUqLUkmILHWy4e/tgjrehVvtPHW+1klDnWcD3S71cPtpYyzqxDtao+ib/So6jpR5mQIn7ZdnW+rGuboldE8Ral/jNmRXPAnY2PpbIQ1k+J91/CWUYNsv7fpuW7VdkvnkyJa0fux1XigBGG9qMBi6ryuqryBEKZV7HtEyhoH7vMVL0+rFVorsRjbuKsY4rHtv2Dylv1+0ObG/9WB+83X2FWpPFJAWcdurL83lpPsFepTt2yjZtrDk21uDH2nmpFVg41txSFcsty/qxLpaWkn0WGKsC42N3gY/hzTfA+FjErvITMD4WsTOo4vhYsS2ZFTcC1fPkhUA4QyAhfubt+aXVU03CTupRF8JrgSiM0ce/fvV6Sj78t6XLiw3X7pePO2Z20sYKDTw3FEloTrWy5WhrWNc6ApbMaAgSDRx3rwhiTAI0cw8BfGtULX+KG2pISGWD0bIPWEr70HyKC436LhUEzroBawNLSDQMyed+L8c1yP0mZjm+QQDCNbMCKUepWvmYIj8RYQmimiBfh6z8LaE2/0iQC7bq9cMx7XqxcmKE4yMJiMViZevcRJa7+eq8/v2HV6fbsq07b2MPrS5df+V9X91Qv3aAfP+cuEm7jV7TD5VM4eLV9PeOCwFYSmfeNTw7MwOn48Obc7/0sFxmrvuNq1/q+SORlY18/F/uL+95qO2T7su0/q9F/6QmXp2RzvSBE2CyJnMP9rKEh09+6cnsUprUCD+Y/mINS/7d0GLg2L2ZbPJTl0XO2ePUys/MzLzyrgviX534t3d0L4pyv46w67DA9y+l2bfvH/zIA6z56NsvvfXNzdxJiQ19ii5qucbeR07/7A83ZjqgPPZOeBC+FlHp2pLKfa6tCwcOrNbtrI39AmxAaGRdtp/yDdscDCU4eXvnLM81Ai8dSne0ZsQ60+cgA8IU+++g4vk/GsjCz/NK7sGBUFQYWZPvi8mjZT4PtX1xTAhk1nyTegMojxltA5aMT2xJ/4egexLS7Ownu0G+878NU1NwErKBR6GFd74PtPKSdzj6HGxCaIGlqngGpieVb5vwZeljfSzUntZO6s4ac7kMnDwJW+VyXqPhmutvwmKLRFMwf27N8sFJYScZWwvd5gF165/7Yhlpe+emoXORY01p+fDpzGrfY2qBNLwHzgBTOsvInuIii4wyZ4T0tJIbhFdzkiZBLPN5qO1nakJcxL9e3IK1T0tn9fYFS8ZHrkr/n4ao5O5kpY/TkDs6DGdEEH512lGqXh7gaH/4OPwJjLbqjD0sZWelo6/Cx/iwwIgb5j6vdWBi2VyOh9ZRKM/z+1xj29RVYOfv8G9x7l/bvtW6c4xdGYe++3Q/FmA2CL3ywTHonoJ1+XCttrERHlULbLL7LQihLql/a1Ybet8JoUjPUb6Db5ZyB8DgvZabsWr7gwPfaeg97JvQbLyxr/crIIatk52fiyo3osw/2QA/qpwyw19CTyTU8fhRrtlBql4ehNQ4G1f7xu+7pWZDv71lqQz/K/5n4ROHYWAw2PDi53PZqwFzuSvjt9wXv1KWPn3vZluhIgvP7KCNDVybGIfe2/WE6HH4sfIIpdgS2Qf7g61pGNCMBcDZRGM6XgPJ4YA0RC1lPra+kG6U2T0GmrGLQk2Zz0Ntn1m/SdjwT2p6/iPwIDRH7LPH5FsF4hrF4kr6ZzLTmYX119YdpOrloWsgxXr2ff3nXsrWW6RK5EwHpuSzmZxkWji0Tvpf+srA4bJ06kLylaOHWhVHwPZf+4ezTy/sHGMhunTtRWY34zmLKAhqdq10qF5DuKI7aDWMk4FVMZmtzX1n16A+0D+/KX3j4N2aO1SZkzGSx0+pvbfEZHc+77FV6pcapXtq1Q4RYEjqhbVAf/uWY59rPbsoD12i5MdqT2pDIIiGOzyrUDMfajkOFk76eJOaEaWp9Y4bFCegBcyfN7yzYZ2Pwg7a2GAsGn0K6lknzCm+yZGXWX9KlpKDiU42/MdB6uh3T2g16ll3hvi26GAIwp9u7ZKezSBFYXxOlhrifl+IxuTJsQNQ7hclavs8TPw709QvhLi2l5nMkZERyYfPQwA6u1jncNDZCX8qPa3y0DUBP5J6YQPibU5vZ/Ty8Fn5pWMdpFr1HorDxDtYGZYd4ltDIP3pDCkJYJxeVMsFYDSlr/nuPwJLmfXDH1Z9V8h9tt34cmZlR95+GXr1+sUk9+XEc0Dj9yiq1H3g/Avw0NhNMHvpa8nLyxCO3wTh8eWPajW+DWGI1C4nPylA5Lsrtw7PMgeiLgD8EflBeP4fnjmYZPLk56Jyvw1W21+5dNfQ8KJvUhsCy++/NOuY/Wwiudq9CAvdyWSiRx5Gh1fvSjCfd7Q2AKFlp9kCvTw8LBP1+UTTivZABbOJu5LKOTxft9LUPQPLl5NNiRHJOTNBLbecGGq++FxZO7d9NR78tRb9e+uho2+vndyh+dhtxW4Jh7gVTwWbU3NRQBRGDJyDoeaOpkqt6stEV8f6my3SjfSO8IJmXHcgdmt70YbRdW9zn8EHPoVs9AI+q89y5Rn8p93MGpetTZdbO5GIm+FX2423yW5jLGK/jwkYH4tAIGMRyFgEAhmLQCBjEchYBGJnYVzbUPkwLVxqObJHeX92THPLq/r847sKrHmLKC9jq3PZMXUtK/MKqv7JpQSXCNr9XgGlVN0tUD6yJIOewcrYlvQT5dpbFFcM2/021mx9iNUAUctOypqRIpUxVWgJEQ6MtbNvepJpvXRSoHRVc1VdGIuind07jDV7jtQpA3bnZr7qAq8ErffeYax5LVniZk/LvGkHOgUIlycvRysrTwVRUsD+7hafoNyKIyplY3MjvPRMZVhL1jjwW5wAuSSUi1nlEV2BNW8R5QDGxyK2AYyPRSCQsQhkLAKBjEUgkLEIZCwCscMwzsdaXy4VPXdvs7MlNe12r2wl6LhNlUPIqvLqjdjJ1YXmz6rqRYxyqTEYzEYbrSyGIVY/Y7cN+y2wTZEzxHHjRdeQVbvv2l1guilsipjkGgN5bLTRy5pCfhBV7hVYI2SNIbCUKkGyhghZYzG9fI5FJFdNjawtQMY8VQzyXO6N4m4kXTqyci/Y2PwIWf1Q+guWCFndnpHcFsLWsJmcw0CN8TWkMPmU5gjVf4PgSnhamM9E/UUD2Grj/VZCVAFjqTczZdy3ltgxwuZaE/OnExmoLcVs2zI2QgvQP+cFU3ut7E5C+ouhs9XOWJK7qrQwiSl443oxo3feJs6lj/vWfHVvY1qMRIqhs7vmyYsU5gLxThnq5EiS4ohnqmTPJVevgHgSbJ5JQOyauQKXSS5q70ISg6NoPLTjFvHIbJP9JoXLusmlHu8+xO5jrClCVnP2tIBS+cg0aWr4ZqaH9/BTZdg2hKwqEhyGcj1q1nEOSheTL9eFvDm5qhuBDKk2lBQfS8l2sv1ppOTWcIUCH7ED8bFFv0Gg4GFCqpIocqIfybpX/djSfT6fKEF8L6iXRtbuXmAkDAIZi0AgYxEIZCxilz95UdsHmdz8alFPK3nvN2ne5KYxKBbcY2bVoEDv8bC5KENcomhvM9ZtnnKb193tDb1dbCtYY22Kioc1hDpa4mERe9MroIaYVzUY1hIqCw6ryeavI5sTYomwVUJpHe+HbfwOQq+DTN3rNtZirIwmyhIqCy6ryVrCAI2RtsZ4WmOUar57QGzHehsK27oUliAdNLJ7nbGO1z4/LW81WY/kIN5toq2vUigeVvee8QrvB8aqhsv7GmrU9jD/Oy3eRy4iRMuuGNrXfcFYUvhJzIlA1PpbvyJW8abFkHEbdRB70SvwGn5PaF6ANXW1ofnLF1PixucCWpDCD2CIPc9Yy8qq1BwfC/nfzEG0pnBWUyVDhK0sV/25IXWja94yrx7iYZ0SEHsBu2/92FLiYRFlAq4f68kRQcLuZ+zCuAJSxtIIZCwCgYxFIGMRCGQsAoGMRSBjsQsQyFgEAhmLQCBjEchYBAIZi0AgYxHIWAQCGYtAIGMRyFgEAhmLQCBjEXuQsZGY/DEW5rgGUTpqDfPcb8tHsViuEOH5sFlIa9heOKszGjFW9RVmsU6NSLqVSQHETjNWDPcqB+/ffK3peLN0tLrZmHzZ8lOp1YG5N8wpt5ywFz4yAvf17vAJOumG2AOMvTN3kEq3vwoZ6Wg9PX9dOZLNGInwqcBJuDuaCHOBcIqlRMP8IxzLgrYQz0XapGJ8IzTFCGR5ls1LWUwgqydljUY4LpQAIctzjalYRLbq5F6OzwqsbEMIBOWYQWjk+EYpNRUKRlk6r9WTEkkwJBn+1tCpKLQxmcFWWUGpjqRmlIuIajqnKNDKpIRjIiRiIbzmuxt1his4f+XvYEY9frj96kbu6A3pqANmOuBa8NiHXuiAEfgroTb9iwsbHXD1Zy88kJFSfj3yH23d01JJfkusv+n1TKRW7IBJKasDXm8+9qHLLOt7fYnPJv5w44HBxYVfvD7bN35WvP09/1ojBPq/kO6Anwj3P1gj/OjKF9Ks5IPHFrluKXUlfGx6g6X/LFfvd1niVe62zz/TAa8tH5neyAZX33hhcpPp19yzWN+zyLI/O3rstRolPaMo8HLqfTPcoeX037W/lcaL7h86ZnbUxq62aIejSVB909Yk6KSemYdHFSt86d5G2JRS2iErp0xBo/h12ZDWiglxPJPYMIimar0tOPTMEym4DaZSkA7BWWiBnnWYnJLNeCoK7Phm1bjD1CQMsINn51ktlt4+kqvHEmen4Cn2cSXA8lK1jfcoOqRgapqVAeiZAt6QLikQgM0fwgaIsIg0290wrwkTA2WNj7blwYklhbDXB750h5ol5aofz/7vi+H3mlJIqh/iSxK5s0PDQ5d7Lh0brtHrqJJTTYMwHqLcoPR49+ahrbHBmrmD0pdRUS7AKcegHo1lDA1YErU8cmsieItchB/Q0+NpPT2nAJ9984b6FF5zP59+q2RNGGGl9pxC2MR1OHeHTYm74PVXzSn02icTA03SUQsER2fG0tCSXy305k+G+9dYo0+MjGSi/ODtg8FojfRFVO8f7Vg+yjnQ0AWCoqyaKAqsgIokXPmpprggn5AgWNIVBAYPnwwgy/bU7JY6TfQ4HAgpR7fVzDo8qqQ79eMxRqjQ3f/zCtRJ367CAB/lBtgnQ1zhmorw3XUbjGscHBVjYZgZ7RubgSB0zsVUF0Q/5qUjrenHoUv6ptZjN0UnfFM/gwMTWu2jrCIA6WIfavqYrgAHvXI2Ym8xluF3Bt4bU+Ywg/2fiNnNZi7Fj2zq3x4auwmev7hyw8UG6Vs9e56T/pOXTQzHbzJUW755ueHCAZi91BNJLEP0c8BFYeZS8sjF51Q/WTpelo5mu5PvvPC85j9fWj1ycSVXj2mdvNCj3QXxyDNqqe5kzyUp++HVi4u5dEk3FW/FYXweL/me8mN3ifMEI6VkC3Co/xxObu12P3Y3MpbTZohtwWczDum1wSUk2W5nbP0u7KaMe3baOX0dObY3/VgEAv1YxN7BivlrI9pYBAIZi0DGIhDIWASiAIyzW64ba9kjt+eX3YdfUDetKyhU3R4MvLbuTa5WCmx3xwViFKF1QMF9xGzqqAlSZedc8+Uw5u6XTXhN87EEitxNyLzjt8P+39slrLGlguU01voklxq6xgq1rbwN0eW/lHjoOLDbNJ245hrPz7JL+/6zsRYDQHObGwIxJRpMgONV8ZGwxJvZpNoV83a3eJOrlnIeY4iPZ01ck0n+mVbOqJrvhjq3TLIDjM3d0TlzIatkTnSnhZ8DFCm2XNG7P3sp5eA7OLdV/CDj0GmavSBQcZ469dYKVJSjLoy1eGumHV6d73i7q1WGnQrL5qd50dWj76AoqWzO611f6tJpZmfLvlMI3U8b7dn6sdR9YCjUQ6RMt/nObdjp2rBx92hFSQLF7J6u1PboEth1Ct1X+0XXe75AxNbiVF1PFa3QNs6AOnrz1PtzEL4mLw61Xlxtav6kvlzu7bj+lWY49ZZJK3xidD8y1s6PNY/66rBlSCSGuUP5UE0wf/g8LpfJV6OeZo9dWye5WRS9mHJMCgqkxLbTnHJNd5dD3T0PjN2qNrgYfUpKrOgzdjR2qx4psosoWyUugk5R/A0CwtWXwCc4jIRBIGMRCGQsAoGMRexOFH7ysoQ4mV92lTUw1qoG8bOc8fRIiVLzQ1tBDZjds/GxK+a5gqpkrH3UrCm6tDyBseb2PMouXgdScut5p60HzGJ8bCUYmzt/U3Csg52hle4f4nO5PHNVgmSyLXnFNErMTdDtnXO+5fGOOnOl75fjmhRpYy1xsA52Zu9M/nn0IjyOufp4TXb85i2LsBVzpZ19g0DkoSyfk+6eniE6pszvtz2SoEh/zpsX4RifavtrmmLiYwt1Wn5Et23379P4WPtxwiVqVo+SIRSqJE6zuDhaUg5TVEx8bKFOU8XYSjNG5lYIjdXHWMeIbscf51XISahGM2LVyeAU0MrcnfvOxJrmY3PPt9Szn05Lc9/L6hOU98mjwjeRewfTfUjYfBubP9LYRs2anLAKxGlSj49Ixergrbx9KXN0MDVPmFYwPpbCfgqQxfjYavc0PNv0nbC01bLXDGJHKVvRantgrgCx03Mdpc1YVNTCiq2pLE93ZKsptLGIYiE0B/nZt95eWw02xtGPRVQ7Rj+YNmwxdeNT3dEds7FCA88NRRKaU61s49Ua1nWNgCUzGoJEA8fdK4IYkwDN3EMA3xpVy5/ihhoSUtlg2c9K2lWc6S6dQ1b0TWprhOMjsriwdVOzBpaQaBiSz/1ejmuQ+03McnyDAIRrZgUc9xM1lG+Q9zofC7MEUenXmPEcSJA7xTrzkWBud3Mw6NIW5rlwa65N223X/PcGGvib3zDuiXa1p61htKKMNez9fWh16for7/uquuW3tNm39HHiJm1759f0QyVTuHg1/b3jQgCW0pl3Dc/OzMDp+PDm3C89LJeZ637j6pd6/khkZSMf/5f7y3sef7ORnLv4x+LXTy7w/Uu+be+d3Ui29CwwTh44AaZdruce7GUJD5/80pPZpTSpEX4w/UVp29HfDS0Gjt2bySY/dVnknD1OrTy57ZEn+j9T872t1x7pXhTlfh1h1yF3DtFbF5be+J4Yffult765KWqk6VN0qdk8IPzi1AYZlNuc6YBy78MtPFgjrKxKRy3q3Sh9rq18p/HA7NmdsLFfgA0IjazL9lO+YZuDoQQn7egGWZ5rlDbIjIHIrE4od1N1ps9BBgRp6+6Diuf/aCALP6/upHlwIBQVRtbk+2LyaJnPI5UJ8CDCh2B6stDuScVJ/am0xfmd1oxPbEn/h6B7EtKsvcluZYP0b8PUFJyEbOBRaHHeT1Qvvw4np5jOqXT7q7rWz2jnkB6jgUwS1sdC7em1XPaduR15k+mFG6CGlZTbLLvzGo3UzM5Jew2zf4vmz7dnbwwRsfKMrYXukMnAb/1zX4z13Ag0DZ2LHGtKy4dPZ1b7HlMLpOE9cEba9zXLyJ7iIovMApwR0tNKbhC0zZYnoQLnM8F0GYZoVNui3iepjCGJNyypH5E33T0ttSadPfs4Dbmjw3BGBOFXp50tt1a+Ruq8Yfnm15e4PKydwydqwvy3BHbLhLnPax0ob3Oq4NP/ZfyqIm24zH3b2vhLU1IfLDr9uzYdjLRVmrEr49B3n+7HAswGoVc+OAbdU+rubWu1jY3wqFpgU9rnG0JdUv/WrDb0vhNCkZ6jfAffLOUOgMF7LT9jRz8EfTCoMMJH230XMEd+1eqHfy6q3IhyawPy6KKcMsNfQk8k1PH4Ua7ZQaZePgBdTyrKJyGs3965c5gcWIw8eRgGBoMNL34+l72qzyl9faL/sCKt3PiHzYsFPajs31easYFrE+PQe7ueED0OP1b6U7Elsg/2B1vTWidJ3Xo20ZiO10ByOCANZUuZj60vpBtldht23Y7qm8uXjbB3DL74KdambLl8w1zzwIuCY67aWlyjmDrZ85nMdGZh/TWnHRr18lc+kvxN6Vvb0OCEYJGq3DCTID1XTE7CgzaCotMstyITTCeTb3ceagHVGbD5d/DowtrJSjMWokvXXmR2M56ziIKgZtdKh6rzBFd0B00a1AKrYjJbm/sO0FUf6J+X9wXn4N2aE1T+h9j3w0sUYEjS1D/GsqfGr7i8S6pTWqvVeqpGOhqSemEt0N++5djnufLRz6XXsgEQVmrP6TvmsnMQlXNQqT3mPj+Za7O8iAqp9BHpfZPkuy6aP9+x+bM0rdQkl4GxwVg0+hTUsy6YU6ZSjrzMXAHJUnIw0cmG/zhIHf3uCa1GPevOEN8WHQxB+NOtXdKzGaQojM/JUkPc7wvRmDzYHYByvx5pOb26IF9jpinnn9TsqpvhCEBnF2uNg85O+FPpaZWHrgn4kdQLzPa1Ob2d0cuHOfHHgzw8DgdCRhM88Q5WRhZ39N/Zw0IIOkNKAhinF4P8XBe7KlqbZUdgObPe3CrTFFT/VRofgi+LNcd3ZD72+sUk9+XEc0Dj9yj8qvvA+RfgobGbYPbS15KXlyEcvwnC48sf1Wp8mzlfkdrl5CcFiHx35dbhWTY41wWAPyL3//w/PHMwyeQxbJT9bXB68k5pRnI2cVdyeNE/qQN3us1zPptIrnYvwkJ3MpnokRIWhlfvSjCjPFobgNCy02yBXv6f6sJfY17H7wy819CMfg4rl3qGujdg+XKyKTEiOWcmHKg7snppWWuzImiv2QzeaEr4wdsV8ga0MWU777yEQ9yKp4LNqbkKvxnZpYiBczDU3NFUqVV9nug6uj4nH9wQXt2oeBdt7y1tdH3NU7ngA59CNnoBn3WeTW542s2YcdnadOX0TNzGb0a4hZ2INsS4AsR2xgSMj0UgkLEIZCwCgYxFIJCxCGQsArGzMK5tqHzkrzNCC26QXVYVtZVqff7xHdV2tscZvt3J2Crd3bRcW7NTTSpFGuxyr4BSqi40Ih9ZkkHPYGVsS/pvYf2/l2ix29sjqs7GGq+gtOSzZWloatk/WVtklpR1eW7LAuq+y0XC7qUnL5trKS2MSuwLlPfKk32zbDqiWBtr40PmfaH5RC4vY9EQIjww1ryWLHEjENmtwys6BXvJK8gzplRfZNbZ/pZ1xgCBNtbOVVXXRTetJWsc+Il1f6nyewUUPQOEBIyPRWwDGB+LQCBjEchYBAIZi0AgYxHIWASiihhLDf+bjzyC2uxRp8R0aTup0fwgL0MKtW1ZDhNz2PxOE5qvrJamZVOzaDdtKAV8bVGV8HV1IZtN2sxvbwnk7yFqKEIdb5W8d6nUlEXAfsdNJY0YyUqM5Ry1kf/iC9zd4xVYI2SNIbCUqkZPj5A1FtPL51hETEaLOvPAfndtozz3om7W33zn6EYdWbknbGx+hKx+KP0FS4SsTgiS20LYGjaT2wqbGuNriL2JNm5DrDRH9F+4ADHXNFOO2tt6dftsyBlZQ9CtozYYI7MLGEu9jffGQFW7LdTthlNi/ix269gClWg+k4txY5z2gacYylDljCX5jyfUjSReuF48SrBt/hPLOC4gqv/JixTmAvFOGUoc+E6cpxyI401CCsxWlDC+29ai+JuH3TVX4PLLPWrvQuqhiIZt1x0ivYm7eTNvy16EJS3NJKIh3e2MNUXI6k8s8qEaM2uOVzV8M//21UNYq1qE2htGU4iufXVSvFxno6spLD2foR9bhSgpPrbAKOuP8+dVyjYnuhDbwQ7Exxb9BqHw2iwVpkORE/1I1r3qx5bu8/lECeJ7Qb00snb3AiNhEMhYBAIZi0AgYxG7/MmL2j7IaIGAxTyt5L3fpHmTm5SYmrW2al3KjeYFyuSHu+hzwnqEIYYM7mHGus1TbvO6u72hd49tVRltDKItGA+rR5IhZfeHV0ANMa9qMKwlVBYcVpPNX0c2J8QSYauE0hZ3PxTFPHxNsA9srMVY6UGyiqEyRMSCy2qyZqaYIm2N8bTGKFU390ALSMk5Fd7iYUH3JNDI7nnGFjBrplhtUyws8WwHiZ3LUSj+y/IbApdXAWphtLP7hbGq4fK+Nhu1Pcz/Tov3kalt0DXxckMgWfcNY0mxrqD5NyzUkVvEA+9tQhspKbIOYv95BV7D7wklVkNJXW2o7gXnZZMSnqC8mGfEXmesHghrmkVyjIgFcxCtKZzVVMkQYas8UhF97oHYqUBJvhwP8bDmE0Di7i3svvVjS4mHRZQJuH6sJ0cECbufsQvjCkgZSyOQsQgEMhaBjEUgkLEIBDIWgYzFLkAgYxEIZCwCgYxFIGMRCGQsAoGMRSBjEQhkLAKBjEUgYxEIZCwCgYxFIGMRuwK0fFW+X3kNkLEItLEIBDIWgVBQg7+ORtd1F4AgY/cTfUnZqngs56cG6BUg0I9FIJCxCAT6sYjdiHrsgr38zGXd4qzIKgXreHukosUv2OfcODJ2j08S5G8N5LGKF5bRItUoAgT92H0NUhrdfbGwPjeONhZR8lhOdqJxZOx+chGKtcu+LXDuY+PoFSAqbkC31TgyFk3s7mocGYuE3c48QOUbxzcIe//hSdpO0PM4r2+C5mUW1duMWQlOhnPjyFjE7gJ6BQhkLAKBjEUgkLGI6oHguSQ+ee01xKT/it7gODbiuityXp4pobQmTQiuuzZnAL6l3XMYqbzM7TfZ71kEegV7FK1Bno/CKRHaToEQ5sOCYgrZv1hTEEY5LthqKKdCbOAiIisRtZaXPkiQYwWFkJxnh9FQIEggmAAxCGIkIEtSRZAgRHkulJLLtYW4R/S2mk5xo6xMTG4nEeZCCWTsvsTqv6SX7ob4O2BjHH6OTwcf07PqrsFQQ4auGsrlRtxA5klp1F2cCz5uKi9h61pDEuCxYDr4c/ZNfkAQw2vArcDzPLQ8KXIthrxrsBrOCIoLmvrHpv+utwXfHX6MGekRuZ3bgpngbcjY/ebIxiTLtn4SQpNwLgNiAHqnYPIpvcBkFAL3PZJSPEelXM6bnIJGnn1uRCefMJWXMBMVBgCeYrJ67ZtMhYCVOPfL8FQA1rthyuCaTrEmxZTaZKZ7fl1pKyiLPTmptROchKmg++nVhfAS7y10jMzMSAN8y/3PH545+yebQy9Bx2/A/Vc3oYOls3/sG6zFnzz7xlnQysnpM3D7b8Cf17OCV6zlTR+5PGuTwoPrIdbkW5f/dUWSdH+9SUT8Ef7sep1UnOUp//953aYmVikkVavdMktHG7s/0LTVvQIQDTSPMrIIINSYJpECyTdD9xjKqRhjBbMSjUGodZh00mXl4caalh+zJhubU0qxrEnE8bW58G/mWlHbspVei17BvsSvL/6C5EcGuucBvhGCrgAAFxWOqLm/NRqdGzaWU5Dugok0+2yBrpSpvA5J1jfsm9z6j8k72MdfdDMvYv1l6GTD+9ioJiKUitb8pXzETbSxrHRIaUulqqjcSSHoXEfG7kv0HWiXru3bcUa9vhZunT3ZJJIH69Tcv3k/37RsLKdgI819ZENiBZd+wVTeIJfJ6rNvMnLPQUnUP49OMUmnuMwiwPJQe05E5KOBpNJk6OwKZSVaA3Jb6jNfgzJN1sKnC4Q54hsERP6z20gVK2dgrMptC4XVCEjqGuBYXMiuFK8px18SWtpvM9TgyZxqxObH7Xk/u7cGXKoaOJ2HIjRfPaMYNYiUpRjO300b6utvp8oHLlPFyhneebn1pt/dTDTelkJYs6YESF7Qet7P7u1+M5/XPDVlEbCvQg23Qo6IxnKO2sh/dwFhoZoJa+vHUkq1Dyr3vvy/kkzVy5H7pl6eXBWgltKgplBNOKhSqFWqdmiSSM2tqYwhehm5Jilg/onlDA1nst3bMp/4FF2titjYfIvA/hGVH0QzL7aLjOQsiEpfYp8P+i84ciINUs2Hpmz1g5ittCaVGkZoIC7juEGb3FhuqEQcSOggl5huIJN35aINktl/xlpo4ZxGbBKJ/YJJJq5R95aIfevEuZLrqjummyxfCeLmLVuZ7NXjsa9FZM+dApLWb8ZS7Zo69y2hPv2indoeFqVL0TedHzVLMZbGcQHhI2NJ4Scx/1YMIZ4sen5rNo1TV6I5aEsLs9PR23BdAo3az7xQ5FxZvIKClsAwD2T6Su2vnFEYdeGSqVFt9so6oDsQhbgpaiV8ETaYlHTHoiGtGGPVIZiYZz0tI7NeSPFcqfGbUz6Yilil5jVArLpQ4tVH0CvkjpQnMEWCVQmb6qSQXNcJNycXStEHubwd+P7Oy/a6VY3n5vMeKh4Zi/AR/x/OV53biPhpawAAAABJRU5ErkJggg==</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-04-04 12:20:23 -0400" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.03" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Allopurinol versus control (placebo or no drug), outcome: 1.3 Severe quadriplegia in surviving infants.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2012-04-04 12:22:08 -0400" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.04" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Allopurinol versus control (placebo or no drug), outcome: 1.4 Seizures during the neonatal period.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2012-04-04 12:25:03 -0400" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.05" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Allopurinol versus control (placebo or no drug), outcome: 1.5 Abnormalities on brain imaging.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2012-05-15 13:11:35 -0400" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>